0001000228-23-000052 | 10-Q | XBRL Viewer

Print Document View Excel Document

Debt - Term Loan Narrative (Details) - Term Credit Agreement [Member] - USD ($)		9 Months Ended
	Jul. 11, 2023	Sep. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Debt face amount	$ 750,000,000	$ 750,000,000
Debt term (in years)	3 years	3 years
Long-term debt		$ 745,000,000	$ 0
Interest Rate Swap [Member]
Line of Credit Facility [Line Items]
Derivative fixed interest rate		5.79%
Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]
Line of Credit Facility [Line Items]
Debt instrument, interest rate, stated percentage		5.33%
Debt instrument, basis spread on variable rate		1.35%
Debt instrument, interest rate at period end		6.68%

Comprehensive Income	9 Months Ended
Comprehensive Income	Sep. 30, 2023
Comprehensive Income [Abstract]
Comprehensive Income	Note 14 – Comprehensive Income Comprehensive income includes certain gains and losses that, under U.S. GAAP, are excluded from net income as such amounts are recorded directly as an adjustment to stockholders’ equity. The following table summarizes our Accumulated other comprehensive loss, net of applicable taxes as of: September 30, December 31, 2023 2022 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (38) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (252) $ (236) Unrealized gain from foreign currency hedging activities 7 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (247) $ (233) Total Accumulated other comprehensive loss $ (286) $ (271) The following table summarizes the components of comprehensive income, net of applicable taxes as follows: Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Net income $ 143 $ 162 $ 419 $ 515 Foreign currency translation loss (45) (89) (17) (176) Tax effect - - - - Foreign currency translation loss (45) (89) (17) (176) Unrealized gain from foreign currency hedging activities 9 15 3 27 Tax effect (3) (4) (1) (7) Unrealized gain from foreign currency hedging activities 6 11 2 20 Pension adjustment gain - 2 - 2 Tax effect - (1) - (1) Pension adjustment gain - 1 - 1 Comprehensive income $ 104 $ 85 $ 404 $ 360 Our financial statements are denominated in the U.S. Dollar currency. Fluctuations in the value of foreign currencies as compared to the U.S. Dollar may have a significant impact on our comprehensive income. The foreign currency translation loss during the nine months ended September 30, 2023 and nine months ended September 24, 2022 was primarily due to changes in foreign currency exchange rates of the Australian Dollar, Brazilian Real, British Pound, Canadian Dollar, Chinese Yuan, and Euro. The following table summarizes our total comprehensive income, net of applicable taxes as follows: Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 100 $ 79 $ 384 $ 350 Comprehensive income attributable to noncontrolling interests 4 2 10 4 Comprehensive income attributable to redeemable noncontrolling interests - 4 10 6 Comprehensive income $ 104 $ 85 $ 404 $ 360

Debt - Other Short-Term Bank Credit Lines Narrative (Details) - USD ($)	Sep. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank credit lines	$ 12,000,000	$ 103,000,000
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	366,000,000	402,000,000
Bank credit lines	$ 12,000,000	$ 103,000,000
Weighted average interest rate on borrowings under credit lines at period end	4.34%	10.11%

Income Taxes - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 24, 2022	Dec. 31, 2022
Income Tax Examination [Line Items]
Effective tax rate	22.50%	23.50%
Tax interest expense (credit)	$ 3	$ 1
Other Liabilities [Member]
Income Tax Examination [Line Items]
Unrecognized tax benefits	110		$ 94
Unrecognized tax benefits that would affect the effective tax rate if recognized	102		80
Total interest	$ 15		$ 12

Fair Value Measurements	9 Months Ended
Fair Value Measurements	Sep. 30, 2023
Fair Value Measurements [Abstract]
Fair Value Measurements	Note 6 – Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity’s own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described as follows: • Level 1— Unadjusted quoted prices in active markets for identical assets or liabilities that are accessible at the measurement date. • Level 2— Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs include: quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability; and inputs that are derived principally from or corroborated by observable market data by correlation or other means. • Level 3— Inputs that are unobservable for the asset or liability. The following section describes the fair values of our financial instruments and the methodologies that we used to measure their fair values. Investments and notes receivable There are no quoted market prices available for investments in unconsolidated affiliates and notes receivable. Certain of our notes receivable contain variable interest rates. We believe the carrying amounts are a reasonable estimate of fair value based on the interest rates in the applicable markets. Debt The fair value of our debt (including bank credit lines, current maturities of long-term debt and long-term debt) is classified as Level 3 within the fair value hierarchy, and as of September 30, 2023 and December 31, 2022 was estimated at $ 1,899 million and $ 1,149 million, respectively. Factors that we considered when estimating the fair value of our debt include market conditions, such as interest rates and credit spreads. Derivative contracts Derivative contracts are valued using quoted market prices and significant other observable inputs. We use derivative instruments to minimize our exposure to fluctuations in foreign currency exchange rates. Our derivative instruments primarily include foreign currency forward agreements related to certain intercompany loans, certain forecasted inventory purchase commitments with foreign suppliers, foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges, hedging of the floating interest rate to a fixed interest rate on our $ 750 million term loan , and a total return swap for the purpose of economically hedging our unfunded non-qualified supplemental executive retirement plan (the “SERP”) and our deferred compensation plan (the “DCP”). The fair values for the majority of our foreign currency derivative contracts are obtained by comparing our contract rate to a published forward price of the underlying market rates, which is based on market rates for comparable transactions and are classified within Level 2 of the fair value hierarchy. Total Return Swaps The fair value for the total return swap is measured by valuing the underlying exchange traded funds of the swap using market-on-close pricing by industry providers as of the valuation date and are classified within Level 2 of the fair value hierarchy. Redeemable noncontrolling interests The values for redeemable noncontrolling interests are classified within Level 3 of the fair value hierarchy and are based on recent transactions and/or implied multiples of earnings. The following table presents our assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of September 30, 2023 and December 31, 2022: September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 30 $ - $ 30 Derivative contracts undesignated - 1 - 1 Total assets $ - $ 31 $ - $ 31 Liabilities: Derivative contracts designated as hedges $ - $ 2 $ - $ 2 Derivative contracts undesignated - 1 - 1 Total return swaps - 4 - 4 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 821 $ 821 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Comprehensive Income (Tables)	9 Months Ended
Comprehensive Income (Tables)	Sep. 30, 2023
Comprehensive Income [Abstract]
Accumulated Other Comprehensive Loss Net of Applicable Taxes	September 30, December 31, 2023 2022 Attributable to redeemable noncontrolling interests: Foreign currency translation adjustment $ (38) $ (37) Attributable to noncontrolling interests: Foreign currency translation adjustment $ (1) $ (1) Attributable to Henry Schein, Inc.: Foreign currency translation adjustment $ (252) $ (236) Unrealized gain from foreign currency hedging activities 7 5 Pension adjustment loss (2) (2) Accumulated other comprehensive loss $ (247) $ (233) Total Accumulated other comprehensive loss $ (286) $ (271)
Components of Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Net income $ 143 $ 162 $ 419 $ 515 Foreign currency translation loss (45) (89) (17) (176) Tax effect - - - - Foreign currency translation loss (45) (89) (17) (176) Unrealized gain from foreign currency hedging activities 9 15 3 27 Tax effect (3) (4) (1) (7) Unrealized gain from foreign currency hedging activities 6 11 2 20 Pension adjustment gain - 2 - 2 Tax effect - (1) - (1) Pension adjustment gain - 1 - 1 Comprehensive income $ 104 $ 85 $ 404 $ 360
Total Comprehensive Income, Net of Applicable Taxes	Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Comprehensive income attributable to Henry Schein, Inc. $ 100 $ 79 $ 384 $ 350 Comprehensive income attributable to noncontrolling interests 4 2 10 4 Comprehensive income attributable to redeemable noncontrolling interests - 4 10 6 Comprehensive income $ 104 $ 85 $ 404 $ 360

Debt - Schedule of Long-term Debt (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Finance lease obligations	$ 10	$ 10
Total	1,887	1,046
Less current maturities	(72)	(6)
Long-term debt	1,815	1,040
Term Credit Agreement [Member]
Debt Instrument [Line Items]
Long-term debt	745	0
Private Placement Facilities [Member]
Debt Instrument [Line Items]
Long-term debt	1,074	699
U.S. Trade Accounts Receivable Securitization [Member]
Debt Instrument [Line Items]
Long-term debt	0	330
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member]
Debt Instrument [Line Items]
Long-term debt	$ 58	$ 7
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] \| Minimum [Member]
Debt Instrument [Line Items]
Borrowing Rate	0.00%	0.00%
Various Collateralized and Uncollateralized Loans Payable with Interest in Varying Installments Through 2023 at Interest Rates Ranging from 0.00% to 3.65% at April 1, 2023 and Ranging from 0.00% to 3.50% at December 31, 2022 [Member] \| Maximum [Member]
Debt Instrument [Line Items]
Borrowing Rate	9.42%	3.50%

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average period of recognition for unrecognized compensation costs on nonvested awards (in years)			2 years 6 months
Grants in period (in shares)			0
Total unrecognized compensation cost related to non-vested awards	$ 83		$ 83
Expected life of options (years)			6 years
After-tax share-based compensation (credit) expense	11	$ 13	$ 30	$ 34
Pre-tax share-based compensation (Credit) expense	$ 14	$ 17	$ 38	$ 44
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years
Percentage of stock options vest per year			33.33%
Expiration period (in years)			10 years
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			4 years
Time-Based Restricted Stock/Restricted Units [Member] \| 2015 Non-Employee Director Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			12 months
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of years for full vesting (in years)			3 years

Business Acquisitions	9 Months Ended
Business Acquisitions	Sep. 30, 2023
Business Acquisitions [Abstract]
Business Acquisitions	Note 5 – Business Acquisitions Our acquisition strategy is focused on investments in companies that add new customers and sales teams, increase our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we have already invested in businesses), and finally, those that enable us to access new products and technologies. In connection with our business acquisitions, the major classes of assets and liabilities to which we generally allocate acquisition consideration to, excluding goodwill, include identifiable intangible assets (i.e., customer relationships and lists, trademarks and trade names, product development and non-compete agreements), inventory and accounts receivable. The estimated fair value of identifiable intangible assets is based on critical judgments and assumptions derived from analysis of market conditions, including discount rates, projected revenue growth rates (which are based on historical trends and assessment of financial projections), estimated customer attrition and projected cash flows. These assumptions are forward-looking and could be affected by future economic and market conditions. While we use our best estimates and assumptions to accurately value assets acquired and liabilities assumed at the acquisition date as well as contingent consideration, where applicable, our estimates are inherently uncertain and subject to refinement. As a result, within 12 months following the date of acquisition, or the measurement period, we may record adjustments to the assets acquired and liabilities assumed with the corresponding offset to goodwill within our condensed consolidated balance sheets. At the end of the measurement period or final determination of the values of such assets acquired or liabilities assumed, whichever comes first, any subsequent adjustments are recognized in our condensed consolidated statements of operations. During the nine months ended September 30, 2023 we completed accounting for certain acquisitions that occurred in the year ended December 31, 2022. In relation to these acquisitions, we did not record material adjustments in our condensed consolidated financial statements relating to changes in estimated values of assets acquired, liabilities assumed and contingent consideration assets and liabilities. Acquisition of S.I.N. Implant System On July 5, 2023 we acquired a 100 % voting equity interest in S.I.N. Implant System (“S.I.N.”), one of Brazil’s leading manufacturers of dental implants. Based in São Paulo and founded in 2003, S.I.N. manufactures an extensive line of products to perform dental implant procedures and is focused on advancing the development of value-priced dental implants. S.I.N. recently expanded the distribution of its products into the United States and other international markets. The following table aggregates the preliminary estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired in the S.I.N.: 2023 Acquisition consideration: Cash $ 326 Total consideration $ 326 Identifiable assets acquired and liabilities assumed: Current assets $ 75 Intangible assets 155 Other noncurrent assets 33 Current liabilities (33) Long-term debt (22) Deferred income taxes (55) Other noncurrent liabilities (27) Total identifiable net assets 126 Goodwill 200 Total net assets acquired $ 326 Goodwill is a result of expected synergies that are expected to originate from the acquisition as well as the expected growth potential of S.I.N. The acquired goodwill is not deductible for tax purposes. The following table summarizes the preliminary identifiable intangible assets acquired as part of the acquisition of S.I.N.: 2023 Estimated Useful Lives (in years) Customer relationships and lists $ 78 10 Trademarks/ Tradenames 9 5 Non-compete agreements 1 5 Product development 38 7 Other 29 5 Total $ 155 The accounting for the acquisition of S.I.N. has not been completed in several areas, including but not limited to pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued liabilities and income and non-income based taxes. To assist management in the allocation of consideration, we engaged valuation specialists to determine the fair value of intangible and tangible assets acquired and liabilities assumed. We will finalize the amounts recognized as the information necessary to complete the analysis is obtained. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. The pro forma financial information has not been presented because the impact of the S.I.N. acquisition during the three and nine months ended September 30, 2023 was immaterial to our condensed consolidated financial statements. Acquisition of Biotech Dental On April 5, 2023, we acquired a 57 % voting equity interest in Biotech Dental (“Biotech Dental”), which is a provider of dental implants, clear aligners, individualized prosthetics, and innovative digital dental software based in France. Biotech Dental has several important solutions for dental practices and dental labs, including Nemotec, a comprehensive, integrated suite of planning and diagnostic software using open architecture that connects disparate medical devices to create a digital view of the patient, offering greater diagnostic accuracy and an improved patient experience. The integration of Biotech Dental’s software with Henry Schein One’s industry-leading practice management software solutions will help customers streamline their clinical as well as administrative workflow for the ultimate benefit of patients. The following table aggregates the preliminary estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired in the Biotech Dental acquisition: 2023 Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 80 Intangible assets 119 Other noncurrent assets 76 Current liabilities (51) Long-term debt (84) Deferred income taxes (38) Other noncurrent liabilities (22) Total identifiable net assets 80 Goodwill 343 Total net assets acquired $ 423 Goodwill is a result of expected synergies that are expected to originate from the acquisition as well as the expected growth potential of Biotech Dental. The acquired goodwill is deductible for tax purposes. 2023 Estimated Useful Lives (in years) Customer relationships and lists $ 60 10 Trademarks/ Tradenames 14 5 Non-compete agreements 1 5 Other 44 5 Total $ 119 The accounting for the acquisition of Biotech Dental has not been completed in several areas, including but not limited to pending assessments of accounts receivable, inventory, intangible assets, right-of-use lease assets, accrued liabilities and income and non-income based taxes. To assist management in the allocation of consideration, we engaged valuation specialists to determine the fair value of intangible and tangible assets acquired and liabilities assumed. We will finalize the amounts recognized as the information necessary to complete the analysis is obtained. We expect to finalize these amounts as soon as possible but no later than one year from the acquisition date. The pro forma financial information has not been presented because the impact of the Biotech Dental acquisition during the three and nine months ended September 30, 2023 was immaterial to our condensed consolidated financial statements. Other 2023 Acquisitions During the nine months ended September 30, 2023, we acquired companies within the health care distribution and technology and value-added services segments. Our acquired ownership interest ranged between 51 % to 100 %. The following table aggregates the preliminary estimated fair value, as of the date of acquisition, of consideration paid and net assets acquired for these acquisitions during the nine months ended September 30, 2023. 2023 Acquisition consideration: Cash $ 167 Deferred consideration 4 Estimated fair value of contingent consideration payable 6 Fair value of previously held equity method investment 29 Redeemable noncontrolling interests 77 Total consideration $ 283 Identifiable assets acquired and liabilities assumed: Current assets $ 32 Intangible assets 117 Other noncurrent assets 18 Current liabilities (23) Deferred income taxes (13) Long-term debt (8) Other noncurrent liabilities (10) Total identifiable net assets 113 Goodwill 170 Total net assets acquired $ 283 Goodwill is a result of the expected synergies and cross-selling opportunities that these acquisitions are expected to provide for us, as well as the expected growth potential. Approximately half of the acquired goodwill is deductible for tax purposes. In connection with an acquisition of a controlling interest of an affiliate, we recognized a gain of approximately $ 18 million related to the remeasurement to fair value of our previously held equity investment, using a discounted cash flow model based on Level 3 inputs, as defined in The following table summarizes the preliminary identifiable intangible assets acquired during the nine months ended September 30, 2023 and their estimated useful lives as of the date of the acquisition: 2023 Estimated Useful Lives (in years) Customer relationships and lists $ 76 2 - 12 Trademarks/ Tradenames 9 5 - 10 Non-compete agreements 2 5 Product development 7 7 Patents 1 10 Other 22 5 Total $ 117 The pro forma financial information has not been presented because the impact of the acquisitions during the three and nine months ended September 30, 2023 was immaterial to our condensed consolidated financial statements. Acquisition Costs During the nine months ended September 30, 2023 and September 24, 2022 we incurred $ 18 million and $ 6 million, respectively, in acquisition costs, which are included in “selling, general and administrative” within our condensed consolidated statements of income.

Plan of Restructuring and Integration Costs - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring costs	$ 11	$ 9	$ 59	$ 9
Midway Dental Supply [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring costs		2
Integration costs		$ 1

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY (Parenthetical) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022	Dec. 31, 2022
Net income attributable to redeemable noncontrolling interests	$ 2	$ 10	$ 11	$ 19	$ 21
Foreign currency translation gain (loss) attributable to redeemable noncontrolling interests	(2)	(6)	(1)	(13)	$ (6)
Unrealized gain (loss) from foreign currency hedging activities, tax (benefit)	3	4	1	7
Pension adjustment gain, tax	$ 0	$ 1	$ 0	$ 1

Income Taxes	9 Months Ended
Income Taxes	Sep. 30, 2023
Income Taxes [Abstract]
Income Taxes	Note 9 – Income Taxes For the nine months ended September 30, 2023 our effective tax rate was 22.5 %, compared to 23.5 % for the prior year period. The difference between our effective tax rate and the federal statutory tax rate primarily relates to state and foreign income taxes and interest expense. The total amount of unrecognized tax benefits, which are included in “other liabilities” within our condensed consolidated balance sheets, as of September 30, 2023 and December 31, 2022 was $ 110 million and $ 94 million, respectively, of which $ 102 million and $ 80 million, respectively, would affect the effective tax rate if recognized. It is possible that the amount of unrecognized tax benefits will change in the next 12 months, which may result in a material impact on our condensed consolidated statements of income. All tax returns audited by the IRS are officially closed through 2019. The tax years subject to examination by the IRS include years 2020 and forward. In addition, limited positions reported in the 2017 tax year are subject to IRS examination. The total amounts of interest and penalties are classified as a component of the provision for income taxes. The amount of tax interest expense was $ 3 million for the nine months ended September 30, 2023 and $ 1 million for the nine months ended September 24, 2022. The total amount of accrued interest is included in “other liabilities,” and was $ 15 million as of September 30, 2023 and $ 12 million as of December 31, 2022. The amount of penalties accrued for during the periods presented were not material to our condensed consolidated financial statements.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Fair Value Measurements (Tables)	9 Months Ended
Fair Value Measurements (Tables)	Sep. 30, 2023
Fair Value Measurements [Abstract]
Assets and Liabilities Measured and Recognized on a Recurring Basis	September 30, 2023 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 30 $ - $ 30 Derivative contracts undesignated - 1 - 1 Total assets $ - $ 31 $ - $ 31 Liabilities: Derivative contracts designated as hedges $ - $ 2 $ - $ 2 Derivative contracts undesignated - 1 - 1 Total return swaps - 4 - 4 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 821 $ 821 December 31, 2022 Level 1 Level 2 Level 3 Total Assets: Derivative contracts designated as hedges $ - $ 23 $ - $ 23 Derivative contracts undesignated - 4 - 4 Total assets $ - $ 27 $ - $ 27 Liabilities: Derivative contracts designated as hedges $ - $ 1 $ - $ 1 Derivative contracts undesignated - 3 - 3 Total return swaps - 3 - 3 Total liabilities $ - $ 7 $ - $ 7 Redeemable noncontrolling interests $ - $ - $ 576 $ 576

Net Sales from Contracts with Customers	9 Months Ended
Net Sales from Contracts with Customers	Sep. 30, 2023
Net Sales from Contracts with Customers [Abstract]
Net sales from Contracts with Customers	Note 3 – Net Sales from Contracts with Customers Net sales are recognized in accordance with policies disclosed in Item 8 of our Annual Report on Form 10-K for the year ended December 31, 2022. Disaggregation of Net Sales The following table disaggregates our net sales by reportable segment and geographic area: Three Months Ended Nine Months Ended September 30, 2023 September 30, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,134 $ 748 $ 1,882 $ 3,447 $ 2,290 $ 5,737 Medical 1,044 26 1,070 2,920 71 2,991 Total health care distribution 2,178 774 2,952 6,367 2,361 8,728 Technology and value-added services 185 25 210 519 75 594 Total net sales $ 2,363 $ 799 $ 3,162 $ 6,886 $ 2,436 $ 9,322 Three Months Ended Nine Months Ended September 24, 2022 September 24, 2022 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,131 $ 654 $ 1,785 $ 3,360 $ 2,106 $ 5,466 Medical 1,088 18 1,106 3,215 59 3,274 Total health care distribution 2,219 672 2,891 6,575 2,165 8,740 Technology and value-added services 155 21 176 469 67 536 Total net sales $ 2,374 $ 693 $ 3,067 $ 7,044 $ 2,232 $ 9,276 Deferred Revenue At September 30, 2023, the current and non-current portion of contract liabilities were $ 86 million and $ 9 million, respectively. During the nine months ended September 30, 2023, we recognized, in net sales, $ 70 million of the amount that was previously deferred at December 31, 2022. At December 31, 2022, the current portion of contract liabilities of $ 86 million was reported in accrued expenses: other, and $ 8 million related to non-current contract liabilities was reported in other liabilities.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

Plan of Restructuring and Integration Costs - Schedule of Restructuring Reserve by Segment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Restructuring Cost and Reserve [Line Items]
Balance, beginning			$ 24
Restructuring and integration costs	$ 11	$ 10	59	$ 10
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(14)
Non-cash impairment on disposal of a business			(1)
Cash payments and other adjustments			43
Balance, ending	27		27
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			21
Restructuring and integration costs			52
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(12)
Non-cash impairment on disposal of a business			(1)
Cash payments and other adjustments			37
Balance, ending	25		25
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Balance, beginning			3
Restructuring and integration costs			7
Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets			(2)
Cash payments and other adjustments			6
Balance, ending	$ 2		$ 2

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Millions	Total	Common Stock $.01 Par Value [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Noncontrolling Interests [Member]
Beginning Balance at Dec. 25, 2021	$ 4,063	$ 1	$ 0	$ 3,595	$ (171)	$ 638
Beginning Balance, shares (in shares) at Dec. 25, 2021		137,145,558
Net income (excluding amounts attributable to redeemable noncontrolling interests)	496			491		5
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	(163)				(162)	(1)
Unrealized gain from foreign currency hedging activities, net of tax	20				20
Pension adjustment gain, net of tax	1				1
Dividends declared	(1)					(1)
Purchase of noncontrolling interests	(7)					(7)
Change in fair value of redeemable securities	18		18
Repurchases and retirement of common stock - Value	(200)		(28)	(172)
Repurchases and retirement of common stock - Shares		(2,529,126)
Stock-based compensation expense - Value	44		44
Stock-based compensation expense - Shares		958,539
Stock issued upon exercise of stock options - Value	2		2
Stock issued upon exercise of stock options - Shares		30,424
Shares withheld for payroll taxes - Value	(30)		(30)
Shares withheld for payroll taxes - Shares		(343,541)
Settlement of stock-based compensation awards - Value	2		2
Settlement of stock-based compensation awards - Shares		(2,967)
Transfer of charges in excess of capital			(8)	8
Ending Balance at Sep. 24, 2022	4,245	$ 1	0	3,922	(312)	634
Ending Balance, shares (in shares) at Sep. 24, 2022		135,258,887
Beginning Balance at Jun. 25, 2022	4,227	$ 1	0	3,834	(241)	633
Beginning Balance, shares (in shares) at Jun. 25, 2022		136,439,560
Net income (excluding amounts attributable to redeemable noncontrolling interests)	152			150		2
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	(83)				(83)
Unrealized gain from foreign currency hedging activities, net of tax	11				11
Pension adjustment gain, net of tax	1				1
Dividends declared	(1)					(1)
Change in fair value of redeemable securities	11		11
Repurchases and retirement of common stock - Value	(90)		(12)	(78)
Repurchases and retirement of common stock - Shares		(1,183,729)
Stock-based compensation expense - Value	17		17
Stock-based compensation expense - Shares		3,640
Stock issued upon exercise of stock options - Shares		597
Shares withheld for payroll taxes - Value	(1)		(1)
Shares withheld for payroll taxes - Shares		(1,194)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		13
Transfer of charges in excess of capital			(16)	16
Ending Balance at Sep. 24, 2022	4,245	$ 1	0	3,922	(312)	634
Ending Balance, shares (in shares) at Sep. 24, 2022		135,258,887
Beginning Balance at Dec. 31, 2022	$ 4,095	$ 1	0	3,678	(233)	649
Beginning Balance, shares (in shares) at Dec. 31, 2022	131,792,817	131,792,817
Net income (excluding amounts attributable to redeemable noncontrolling interests)	$ 408			398		10
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	(16)				(16)
Unrealized gain from foreign currency hedging activities, net of tax	2				2
Pension adjustment gain, net of tax	0
Dividends declared	(28)					(28)
Change in fair value of redeemable securities	14		14
Initial noncontrolling interests and adjustments related to business acquisitions	(2)		0			(2)
Repurchases and retirement of common stock - Value	(201)		(26)	(175)
Repurchases and retirement of common stock - Shares		(2,521,695)
Stock-based compensation expense - Value	38		38
Stock-based compensation expense - Shares		1,060,883
Stock issued upon exercise of stock options - Value	$ 1		1
Stock issued upon exercise of stock options - Shares	21,204	19,744
Shares withheld for payroll taxes - Value	$ (32)		(32)
Shares withheld for payroll taxes - Shares		(415,048)
Settlement of stock-based compensation awards - Value	1		1
Settlement of stock-based compensation awards - Shares		(818)
Transfer of charges in excess of capital			4	(4)
Ending Balance at Sep. 30, 2023	$ 4,280	$ 1	0	3,897	(247)	629
Ending Balance, shares (in shares) at Sep. 30, 2023	129,935,883	129,935,883
Beginning Balance at Jul. 01, 2023	$ 4,186	$ 1	0	3,769	(210)	626
Beginning Balance, shares (in shares) at Jul. 01, 2023		130,576,806
Net income (excluding amounts attributable to redeemable noncontrolling interests)	141			137		4
Foreign currency translation loss (excluding loss amounts attributable to redeemable noncontrolling interests)	(43)				(43)
Unrealized gain from foreign currency hedging activities, net of tax	6				6
Pension adjustment gain, net of tax	0
Dividends declared	(1)					(1)
Change in fair value of redeemable securities	28		28
Initial noncontrolling interests and adjustments related to business acquisitions	(1)		(1)			0
Repurchases and retirement of common stock - Value	(50)		(6)	(44)
Repurchases and retirement of common stock - Shares		(659,681)
Stock-based compensation expense - Value	14		14
Stock-based compensation expense - Shares		23,985
Stock issued upon exercise of stock options - Shares		3,884
Shares withheld for payroll taxes - Value	0		0
Shares withheld for payroll taxes - Shares		(9,183)
Settlement of stock-based compensation awards - Value	0		0
Settlement of stock-based compensation awards - Shares		72
Transfer of charges in excess of capital			(35)	35
Ending Balance at Sep. 30, 2023	$ 4,280	$ 1	$ 0	$ 3,897	$ (247)	$ 629
Ending Balance, shares (in shares) at Sep. 30, 2023	129,935,883	129,935,883

Supplemental Cash Flow Information	9 Months Ended
Supplemental Cash Flow Information	Sep. 30, 2023
Supplemental Cash Flow information [Abstract]
Supplemental Cash Flow Information	Note 16 – Supplemental Cash Flow Information Cash paid for interest and income taxes was: Nine Months Ended September 30, September 24, 2023 2022 Interest $ 52 $ 29 Income taxes 178 235 During the nine months ended September 30, 2023 and September 24, 2022, we had $ 3 million and $ 27 million of non-cash net unrealized gains related to foreign currency hedging activities, respectively. additional information related to our total return swap and our interest rate swap agreements.

Business Acquisitions - Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives (Details) - USD ($) $ in Millions			9 Months Ended
	Jul. 05, 2023	Apr. 05, 2023	Sep. 30, 2023
S.I.N [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 155
S.I.N [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 78
Estimated useful lives (in years)	10 years
S.I.N [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 9
Estimated useful lives (in years)	5 years
S.I.N [Member] \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 1
Estimated useful lives (in years)	5 years
S.I.N [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 38
Estimated useful lives (in years)	7 years
S.I.N [Member] \| Other Intangible Assets [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired	$ 29
Estimated useful lives (in years)	5 years
Biotech Dental [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 119
Biotech Dental [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 60
Estimated useful lives (in years)			10 years
Biotech Dental [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 14
Estimated useful lives (in years)			5 years
Biotech Dental [Member] \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 1
Estimated useful lives (in years)			5 years
Biotech Dental [Member] \| Other Intangible Assets [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired			$ 44
Estimated useful lives (in years)			5 years
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 117
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 76
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		2 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Customer Relationships and Lists [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		12 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks/Tradenames [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 9
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks/Tradenames [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Trademarks/Tradenames [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Estimated useful lives (in years)		10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Noncompete Agreements [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 2
Estimated useful lives (in years)		5 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Product Development [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 7
Estimated useful lives (in years)		7 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Patents [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 1
Estimated useful lives (in years)		10 years
Series Of Individually Immaterial Business Acquisitions [Member] \| Other Intangible Assets [Member]
Business Acquisition [Line Items]
Identifiable intangible assets acquired		$ 22
Estimated useful lives (in years)		5 years

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022
Cash flows from operating activities:
Net income	$ 419	$ 515
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	180	160
Non-cash restructuring charges	13	0
Stock-based compensation expense	38	44
Provision for losses on trade and other accounts receivable	7	2
Benefit from deferred income taxes	(4)	(20)
Equity in earnings of affiliates	(10)	(12)
Distributions from equity affiliates	12	12
Changes in unrecognized tax benefits	5	1
Other	(11)	(25)
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable	(72)	(93)
Inventories	180	(9)
Other current assets	(55)	(96)
Accounts payable and accrued expenses	(170)	(131)
Net cash provided by operating activities	532	348
Cash flows from investing activities:
Purchases of fixed assets	(108)	(67)
Payments related to equity investments and business acquisitions, net of cash acquired	(668)	(127)
Proceeds from loan to affiliate	4	9
Other	(36)	(26)
Net cash used in investing activities	(808)	(211)
Cash flows from financing activities:
Net change in bank borrowings	(98)	51
Proceeds from issuance of long-term debt	1,158	165
Principal payments for long-term debt	(457)	(58)
Debt issuance costs	(3)	0
Proceeds from issuance of stock upon exercise of stock options	1	2
Payments for repurchases and retirement of common stock	(200)	(200)
Payments for taxes related to shares withheld for employee taxes	(34)	(30)
Distributions to noncontrolling shareholders	(41)	(18)
Acquisitions of noncontrolling interests in subsidiaries	(19)	(33)
Net cash provided by (used in) financing activities	307	(121)
Effect of exchange rate changes on cash and cash equivalents	18	(11)
Net change in cash and cash equivalents	49	5
Cash and cash equivalents, beginning of period	117	118
Cash and cash equivalents, end of period	$ 166	$ 123

Redeemable Noncontrolling Interests (Tables)	9 Months Ended
Redeemable Noncontrolling Interests (Tables)	Sep. 30, 2023
Redeemable Noncontrolling Interests [Abstract]
Components of the Change in Redeemable Noncontrolling Interests	September 30, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (19) (31) Increase in redeemable noncontrolling interests due to business acquisitions 281 4 Net income attributable to redeemable noncontrolling interests 11 21 Dividends declared (13) (21) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (1) (6) Change in fair value of redeemable securities (14) (4) Balance, end of period $ 821 $ 576

Basis of Presentation - Narrative (Details) - Variable Interest Entity, Primary Beneficiary [Member] - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Asset Pledged as Collateral [Member]
Pledged assets	$ 0	$ 327
Recourse [Member]
Liabilities of VIE	$ 0	$ 255

Debt	9 Months Ended
Debt	Sep. 30, 2023
Debt [Abstract]
Debt	Note 8 – Debt Bank Credit Lines Bank credit lines consisted of the following: September 30, December 31, 2023 2022 Revolving credit agreement $ - $ - Other short-term bank credit lines 12 103 Total $ 12 $ 103 Revolving Credit Agreement On August 20, 2021 , we entered into a $ 1.0 billion revolving credit agreement (the “Revolving Credit Agreement”) which was scheduled to mature on August 20, 2026 . On July 11, 2023 , we amended and restated the Revolving Credit Agreement to, among other things, extend the maturity date to July 11, 2028 and update the interest rate provisions to reflect the current market approach for a multicurrency facility. The interest rate on this revolving credit facility is based on Term Secured Overnight Financing Rate (“Term SOFR”) plus a spread based on our leverage ratio at the end of each financial reporting quarter. The Revolving Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements. As of September 30, 2023 and December 31, 2022, we had $ 0 million and $ 0 million in borrowings, respectively under this revolving credit facility. As of September 30, 2023 and December 31, 2022, there were $ 9 million and $ 9 million of letters of credit, respectively, provided to third parties under this credit facility. Other Short-Term Bank Credit Lines As of September 30, 2023 and December 31, 2022, we had various other short-term bank credit lines available, in various currencies, with a maximum borrowing capacity of $ 366 million and $ 402 million, respectively. As of September 30, 2023 and December 31, 2022, $ 12 million and $ 103 million, respectively, were outstanding. At September 30, 2023 and December 31, 2022, borrowings under all of these credit lines had a weighted average interest rate of 4.34 % and 10.11 %, respectively. Long-term debt Long-term debt consisted of the following: September 30, December 31, 2023 2022 Private placement facilities $ 1,074 $ 699 U.S. trade accounts receivable securitization - 330 Term loan 745 - Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 9.42 % at September 30, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 58 7 Finance lease obligations 10 10 Total 1,887 1,046 Less current maturities (72) (6) Total long-term debt $ 1,815 $ 1,040 Private Placement Facilities Our private placement facilities include four insurance companies, have a total facility amount of $ 1.5 billion, and are available on an uncommitted basis at fixed rate economic terms to be agreed upon at the time of issuance, from time to time through October 20, 2026 . The facilities allow us to issue senior promissory notes to the lenders at a fixed rate based on an agreed upon spread over applicable treasury notes at the time of issuance. The term of each possible issuance will be selected by us and can range from five to 15 years (with an average life no longer than 12 years ). The proceeds of any issuances under the facilities will be used for general corporate purposes, including working capital and capital expenditures, to refinance existing indebtedness, and/or to fund potential acquisitions. The agreements provide, among other things, that we maintain certain maximum leverage ratios, and contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions, disposal of assets and certain changes in ownership. These facilities contain make-whole provisions in the event that we pay off the facilities prior to the applicable due dates. The components of our private placement facility borrowings, which have a weighted average interest rate of 3.65 %, as of September 30, 2023 are presented in the following table: Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,074 U.S. Trade Accounts Receivable Securitization We have a facility agreement based on the securitization of our U.S. trade accounts receivable that is structured as an asset-backed securitization program with pricing committed for up to three years . This facility agreement has a purchase limit of $ 450 million with two banks as agents, and expires on December 15, 2025 . As of September 30, 2023 and December 31, 2022, the borrowings outstanding under this securitization facility were $ 0 million and $ 330 million, respectively. At September 30, 2023, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 5.59 % plus 0.75 %, for a combined rate of 6.34 %. At December 31, 2022, the interest rate on borrowings under this facility was based on the asset-backed commercial paper rate of 4.58 % plus 0.75 %, for a combined rate of 5.33 %. If our accounts receivable collection pattern changes due to customers either paying late or not making payments, our ability to borrow under this facility may be reduced. We are required to pay a commitment fee of 30 to 35 basis points depending upon program utilization. Term Loan On July 11, 2023, we entered into a three-year $ 750 million term loan credit agreement (the “Term Credit Agreement”). The interest rate on this term loan is based on the Term SOFR plus a spread based on our leverage ratio at the end of each financial reporting quarter. This term loan matures on July 11, 2026. As of September 30, 2023, the borrowings outstanding under this term loan were $ 745 million. At September 30, 2023, the interest on this Term Credit Agreement was 5.33 % plus 1.35 % for a combined rate of 6.68 %. However, we have a hedge in place that ultimately creates an effective fixed rate of 5.79 %. The Term Credit Agreement requires, among other things, that we maintain certain maximum leverage ratios. Additionally, the Term Credit Agreement contains customary representations, warranties and affirmative covenants as well as customary negative covenants, subject to negotiated exceptions, on liens, indebtedness, significant corporate changes (including mergers), dispositions and certain restrictive agreements.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Supplemental Cash Flow Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Supplemental Cash Flow Information [Abstract]
Interest			$ 52	$ 29
Income taxes			178	235
Non-cash net unrealized gains related to foreign currency hedging activities	$ 9	$ 15	$ 3	$ 27

Debt - Private Placement Facilities Narrative (Details) - Private Placement Facilities [Member]	9 Months Ended
	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Number of companies included in private placement facilities	4
Debt instrument maximum borrowing capacity	$ 1,500,000,000
Debt instrument, maturity date	Oct. 20, 2026
Average term of issuances under private placement facilities	12 years
Weighted average interest rate at period end	3.65%
Minimum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	5 years
Maximum [Member]
Debt Instrument [Line Items]
Term of issuances under private placement facilities	15 years

Business Acquisitions - Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired (Details) - USD ($) $ in Millions			9 Months Ended
	Jul. 05, 2023	Apr. 05, 2023	Sep. 30, 2023	Dec. 31, 2022
Identifiable assets acquired and liabilities assumed:
Goodwill			$ 3,595	$ 2,893
S.I.N [Member]
Acquisition consideration:
Cash	$ 326
Total consideration	326
Identifiable assets acquired and liabilities assumed:
Current assets	75
Intangible assets	155
Other noncurrent assets	33
Current liabilities	(33)
Long-term debt	(22)
Deferred income taxes	(55)
Other noncurrent liabilities	(27)
Total identifiable net assets	126
Goodwill	200
Total net assets acquired	$ 326
Biotech Dental [Member]
Acquisition consideration:
Cash		$ 216
Fair value of contributed equity share in a controlled subsidiary		25
Redeemable noncontrolling interests		182
Total consideration		423
Identifiable assets acquired and liabilities assumed:
Current assets		80
Intangible assets		119
Other noncurrent assets		76
Current liabilities		(51)
Long-term debt		(84)
Deferred income taxes		(38)
Other noncurrent liabilities		(22)
Total identifiable net assets		80
Goodwill		343
Total net assets acquired		$ 423
Series Of Individually Immaterial Business Acquisitions [Member]
Acquisition consideration:
Cash			167
Deferred consideration			4
Other			6
Fair value of contributed equity share in a controlled subsidiary			29
Redeemable noncontrolling interests			77
Total consideration			283
Identifiable assets acquired and liabilities assumed:
Current assets			32
Intangible assets			117
Other noncurrent assets			18
Current liabilities			(23)
Long-term debt			(8)
Deferred income taxes			(13)
Other noncurrent liabilities			(10)
Total identifiable net assets			113
Goodwill			170
Total net assets acquired			$ 283

Earnings Per Share - Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Weighted-average common shares outstanding:
Basic (in shares)	130,388,353	135,608,678	130,888,717	136,731,413
Effect of dilutive securities:
Stock options and restricted stock units	1,053,782	1,475,371	1,260,455	1,756,841
Diluted (in shares)	131,442,135	137,084,049	132,149,172	138,488,254

Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards (Policy)	9 Months Ended
	Sep. 30, 2023
Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards [Abstract]
Accounting Standard Adopted and Recently Issued Accounting Standards	Accounting Standard Adopted During the quarter ended September 30, 2023, we adopted Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform (Topic 848). The adoption of Topic 848 did not have a material impact on our condensed consolidated financial statements. Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations,” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended roll forward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME [Abstract]
Net income	$ 143	$ 162	$ 419	$ 515
Other comprehensive income (loss), net of tax:
Foreign currency translation loss	(45)	(89)	(17)	(176)
Unrealized gain from foreign currency hedging activities	6	11	2	20
Pension adjustment gain	0	1	0	1
Other comprehensive loss, net of tax	(39)	(77)	(15)	(155)
Comprehensive income	104	85	404	360
Less: Comprehensive income attributable to noncontrolling interests:
Net income	(6)	(12)	(21)	(24)
Foreign currency translation loss	2	6	1	14
Comprehensive income attributable to noncontrolling interests	(4)	(6)	(20)	(10)
Comprehensive income attributable to Henry Schein, Inc.	$ 100	$ 79	$ 384	$ 350

Fair Value Measurements - Assets and Liabilities Measured and Recognized on a Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Dec. 25, 2021
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	$ 821	$ 576	$ 613
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	31	27
Liabilities [Abstract]
Total liabilities	7	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	821	576
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	30	23
Liabilities [Abstract]
Derivative contracts - liabilities	2	1
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	1	4
Liabilities [Abstract]
Derivative contracts - liabilities	1	3
Fair value, measurements, recurring [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps	4
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps		0
Fair value, measurements, recurring [Member] \| Level 1 [Member] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	31	27
Liabilities [Abstract]
Total liabilities	7	7
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	0	0
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	30	23
Liabilities [Abstract]
Derivative contracts - liabilities	2	1
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	1	4
Liabilities [Abstract]
Derivative contracts - liabilities	1	3
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps		3
Fair value, measurements, recurring [Member] \| Level 2 [Member] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps	4
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain]
Assets [Abstract]
Total assets	0	0
Liabilities [Abstract]
Total liabilities	0	0
Attributable To Redeemable Noncontrolling Interests [Abstract]
Redeemable noncontrolling interests	821	576
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts designated as hedges [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Derivative contracts undesignated [Member]
Assets [Abstract]
Derivative contracts - assets	0	0
Liabilities [Abstract]
Derivative contracts - liabilities	0	0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Fair Value Measurement [Domain] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps		$ 0
Fair value, measurements, recurring [Member] \| Level 3 [Member] \| Total return swap [Member]
Liabilities [Abstract]
Total return swaps	$ 0

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 166	$ 117
Accounts receivable, net of allowance for credit losses of $72 and $65	1,573	1,442
Inventories, net	1,833	1,963
Prepaid expenses and other	541	466
Total current assets	4,113	3,988
Property and equipment, net	474	383
Operating lease right-of-use assets	323	284
Goodwill	3,595	2,893
Other intangibles, net	834	587
Investments and other	471	472
Total assets	9,810	8,607
Current liabilities:
Accounts payable	953	1,004
Bank credit lines	12	103
Current maturities of long-term debt	72	6
Operating lease liabilities	74	73
Accrued expenses:
Payroll and related	274	314
Taxes	137	132
Other	571	592
Total current liabilities	2,093	2,224
Long-term debt	1,815	1,040
Deferred income taxes	91	36
Operating lease liabilities	314	275
Other liabilities	396	361
Total liabilities	4,709	3,936
Redeemable noncontrolling interests	821	576
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.01 par value, 1,000,000 shares authorized, none outstanding	0	0
Common stock, $0.01 par value, 480,000,000 shares authorized,129,935,883 outstanding on September 30, 2023 and 131,792,817 outstanding on December 31, 2022	1	1
Additional paid-in capital	0	0
Retained earnings	3,897	3,678
Accumulated other comprehensive loss	(247)	(233)
Total Henry Schein, Inc. stockholders' equity	3,651	3,446
Noncontrolling interests	629	649
Total stockholders' equity	4,280	4,095
Total liabilities, redeemable noncontrolling interests and stockholders' equity	$ 9,810	$ 8,607

Plan of Restructuring and Integration Costs (Tables)	9 Months Ended
Plan of Restructuring and Integration Costs (Tables)	Sep. 30, 2023
Plan of Restructuring and Integration Costs [Abstract]
Schedule of Restructuring Costs and Integration Costs	Three Months Ended September 30, 2023 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 3 - 1 4 Exit and other related costs 1 - - 1 Total restructuring and integration costs $ 10 $ - $ 1 $ 11 Three Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 2 - - 2 Exit and other related costs 1 - - 1 Integration employee-related and other costs - 1 - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ 10 Nine Months Ended September 30, 2023 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 36 $ - $ 4 $ 40 Accelerated depreciation and amortization 12 - 2 14 Exit and other related costs 3 - 1 4 Loss on disposal of a business 1 - - 1 Total restructuring and integration costs $ 52 $ - $ 7 $ 59 Nine Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 2 - - 2 Exit and other related costs 1 - - 1 Integration employee-related and other costs - 1 - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ 10
Schedule of Restructuring Reserve by Segment	Technology and Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring and integration costs 52 7 59 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (12) (2) (14) Non-cash impairment on disposal of a business 1 - 1 Cash payments and other adjustments (37) (6) (43) Balance, September 30, 2023 $ 25 $ 2 $ 27

Debt - U.S. Trade Accounts Receivable Securitization Narrative (Details) - U.S. Trade Accounts Receivable Securitization [Member]	9 Months Ended	12 Months Ended
	Sep. 30, 2023 USD ($) number	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Pricing commitment period	3 years
Debt Instrument, Maturity Date	Dec. 15, 2025
Debt instrument maximum borrowing capacity	$ 450,000,000
Long-term debt	$ 0	$ 330,000,000
Commitment fee for facility usage - facility limit less than fifty percent usage (as a percent)	0.30%
Commitment fee for facility usage - facility limit greater than or equal to fifty percent usage (as a percent)	0.35%
Number of banks as agents for debt instrument \| number	2
Average Asset Backed Commercial Paper Rate [Member]
Debt Instrument [Line Items]
Debt instrument, interest rate at period end	6.34%	5.33%
Debt instrument, variable rate basis at period end	5.59%	4.58%
Debt instrument, basis spread on variable rate	0.75%	0.75%

Debt - Schedule of Private Placement Facility Borrowings (Details) - Private Placement Facilities [Member] - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Less: Deferred debt issuance costs	$ (1)
Total	$ 1,074	$ 699
Debt Instrument, Maturity Date	Oct. 20, 2026
Private Placement Facilities 1 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 20, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.45%
Debt Instrument, Maturity Date	Jan. 20, 2024
Private Placement Facilities 2 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Dec. 24, 2012
Long-term Debt, Gross	$ 50
Borrowing Rate	3.00%
Debt Instrument, Maturity Date	Dec. 24, 2024
Private Placement Facilities 3 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 16, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.42%
Debt Instrument, Maturity Date	Jun. 16, 2027
Private Placement Facilities 4 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 15, 2017
Long-term Debt, Gross	$ 100
Borrowing Rate	3.52%
Debt Instrument, Maturity Date	Sep. 15, 2029
Private Placement facilities 5 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jan. 02, 2018
Long-term Debt, Gross	$ 100
Borrowing Rate	3.32%
Debt Instrument, Maturity Date	Jan. 02, 2028
Private Placement Facilities 6 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Sep. 02, 2020
Long-term Debt, Gross	$ 100
Borrowing Rate	2.35%
Debt Instrument, Maturity Date	Sep. 02, 2030
Private Placement Facilities 7 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.48%
Debt Instrument, Maturity Date	Jun. 02, 2031
Private Placement Facilities 8 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	Jun. 02, 2021
Long-term Debt, Gross	$ 100
Borrowing Rate	2.58%
Debt Instrument, Maturity Date	Jun. 02, 2033
Private Placement Facilities 9 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.79%
Debt Instrument, Maturity Date	May 04, 2028
Private Placement Facilities 10 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.84%
Debt Instrument, Maturity Date	May 04, 2030
Private Placement Facilities 11 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 75
Borrowing Rate	4.96%
Debt Instrument, Maturity Date	May 04, 2033
Private Placement Facilities 12 [Member]
Debt Instrument [Line Items]
Debt Instrument, Issuance Date	May 04, 2023
Long-term Debt, Gross	$ 150
Borrowing Rate	4.94%
Debt Instrument, Maturity Date	May 04, 2033

Stock-Based Compensation - Summary of Stock Option Activity under the Plans (Details) - USD ($) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Outstanding at beginning of period (in shares)	1,117,574
Exercised (in shares)	(21,204)
Forfeited (in shares)	(10,399)
Outstanding at end of period (in shares)	1,085,971
Weighted Average Exercise Price Per Share [Abstract]
Outstanding at beginning of period (in dollars per share)	$ 71.38
Exercised (in dollars per share)	62.74
Forfeited (in dollars per share)	78.32
Outstanding at end of period (in dollars per share)	$ 71.48
Outstanding at end of period, Weighted Average Remaining Contractual Life in Years	7 years 9 months 18 days
Outstanding at end of period, Aggregate Intrinsic Value	$ 8
Options exercisable (in shares)	573,620
Weighted average exercise price, options exercisable (in dollars per share)	$ 68.39

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023 shares
Insider Trading Arr [Line Items]
Material Terms of Trading Arrangement	Rule 10b5-1 Trading Arrangements During the three months ended September 30, 2023, (i) Stanley M. Bergman , the Company’s Chairman of the Board and Chief Executive Officer , on behalf of himself and a family trust for which his wife serves as co-trustee, and (ii) James P. Breslawski , the Company’s Vice Chairman and President , each adopted a Rule 10b5-1 trading arrangement which is a trading plan for the future sale of securities that is intended to satisfy the affirmative defense of Exchange Act Rule 10b5-1 (c), as well as the requirements of the Company’s insider trading policy. Each plan is subject to an initial “cooling off” period during which there may be no transactions between the adoption date and a date that is the later of 90 days or two business days following the Company’s filing of its next quarterly report on Form 10-Q or Annual Report on form 10-K. On September 8, 2023 , Mr. Bergman and the Bergman Family 2010 Trust #2 adopted the trading plan to sell a total of 56,886 shares ( 40,152 shares to be sold by Mr. Bergman and 16,734 shares to be sold by the Bergman Family 2010 Trust #2) based on limit orders at specified prices, with a term of eight months ( i.e., through May 7, 2024). On September 19, 2023 , Mr. Breslawski adopted the trading plan to sell 9,085 shares based on limit orders at specified prices, with a term through December 31, 2024.
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false
Stanley M. Bergman [Member]
Insider Trading Arr [Line Items]
Name	Stanley M. Bergman
Title	Chairman of the Board and Chief Executive Officer
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 8, 2023
Aggregate Available	40,152
James P. Breslawski [Member]
Insider Trading Arr [Line Items]
Name	James P. Breslawski
Title	Vice Chairman and President
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 19, 2023
Aggregate Available	9,085
Bergman Family 2010 Trust #2 [Member]
Insider Trading Arr [Line Items]
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 8, 2023
Aggregate Available	16,734
Stanley M. Bergman and Bergman Family 2010 Trust #2 [Member]
Insider Trading Arr [Line Items]
Rule 10b5-1 Arrangement Adopted	true
Adoption Date	September 8, 2023
Aggregate Available	56,886

Fair Value Measurements - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Estimate of Fair Value Measurement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair value of debt (including bank credit lines)	$ 1,899	$ 1,149

Basis of Presentation	9 Months Ended
Basis of Presentation	Sep. 30, 2023
Basis of Presentation [Abstract]
Basis of Presentation	Note 1 – Basis of Presentation Our condensed consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries (“we”, “us” or “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows. Our accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnote disclosures required by U.S. GAAP for complete financial statements. The unaudited interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes to the consolidated financial statements contained in our Annual Report on Form 10-K for the year ended December 31, 2022 and with the information contained in our other publicly- available filings with the Securities and Exchange Commission. The condensed consolidated financial statements reflect all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position for the interim periods presented. All such adjustments are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 30, 2023. Our condensed consolidated financial statements reflect estimates and assumptions made by us that affect, among other things, our goodwill, long-lived asset and definite-lived intangible asset valuation; inventory valuation; equity investment valuation; assessment of the annual effective tax rate; valuation of deferred income taxes and income tax contingencies; the allowance for doubtful accounts; hedging activity; supplier rebates; measurement of compensation cost for certain share-based performance awards and cash bonus plans; and pension plan assumptions. We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At September 30, 2023 and December 31, 2022, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 0 million and $ 327 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 0 million and $ 255 million, respectively.

Related Party Transactions - Narrative (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Current operating lease liabilities	$ 74.0		$ 74.0		$ 73.0
Noncurrent operating lease liabilities	314.0		$ 314.0		275.0
Equity Method Investee [Member]
Related Party Transaction [Line Items]
Description of the transaction			During our normal course of business, we have interests in entities that we account for under the equity accounting method.
Other liabilities	5.0		$ 5.0		6.0
Due from related party	33.0		33.0		36.0
Revenues	10.0	$ 13.0	33.0	$ 35.0
Purchases from related party	1.0	1.0	$ 7.0	9.0
Internet Brands Inc [Member] \| Royalty Agreements [Member]
Related Party Transaction [Line Items]
Period covered by agreement			10 years
Related party agreement amount			$ 31.0
Operating costs and expenses	8.0	$ 8.0	23.0	$ 23.0
Other liabilities	10.0		10.0		$ 9.0
Employees and Minority Shareholders [Member]
Related Party Transaction [Line Items]
Current operating lease liabilities	5.0		5.0
Noncurrent operating lease liabilities	$ 24.0		$ 24.0
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			6.90%
Employees and Minority Shareholders [Member] \| Operating Lease Liabilities, Non-Current [Member] \| Related Party Concentration Risk[Member]
Related Party Transaction [Line Items]
Concentration risk percentage			7.60%
Employees and Minority Shareholders [Member] \| Minimum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	1 year		1 year
Employees and Minority Shareholders [Member] \| Maximum [Member]
Related Party Transaction [Line Items]
Remaining operating lease term	14 years		14 years

Derivatives and Hedging Activities - Narrative (Details) € in Millions		3 Months Ended		9 Months Ended
	Jul. 11, 2023 USD ($)	Sep. 30, 2023 USD ($)	Sep. 24, 2022 USD ($)	Sep. 30, 2023 USD ($)	Sep. 24, 2022 USD ($)	Dec. 31, 2022 EUR (€)	Mar. 20, 2020 USD ($)
Term Credit Agreement [Member]
Derivative [Line Items]
Debt face amount	$ 750,000,000	$ 750,000,000		$ 750,000,000
Debt term (in years)	3 years			3 years
Foreign Exchange Forward [Member] \| Other Comprehensive Income [Member]
Derivative [Line Items]
Gain (loss) on derivative		4,000,000	$ 15,000,000	$ 1,000,000	$ 26,000,000
Interest Rate Swap [Member] \| Term Credit Agreement [Member]
Derivative [Line Items]
Notional amount		$ 745,000,000		$ 745,000,000
Derivative fixed interest rate		5.79%		5.79%
Interest Rate Swap [Member] \| Other Comprehensive Income [Member] \| Term Credit Agreement [Member]
Derivative [Line Items]
Gain (loss) on derivative		$ 4,000,000		$ 4,000,000
Forward Contracts [Member] \| Net Investment Hedging [Member]
Derivative [Line Items]
Maturity date				Nov. 16, 2023
Notional amount \| €						€ 200
Total Return Swap [Member] \| SERP and DCP [Member]
Derivative [Line Items]
Notional amount		86,000,000		$ 86,000,000			$ 43,000,000
Gain (loss) on derivative		$ (7,000,000)	$ (2,000,000)	$ (1,000,000)	$ (8,000,000)
Inception date				Mar. 20, 2020
Total Return Swap [Member] \| SERP and DCP [Member] \| Secured Overnight Financing Rate Sofr Overnight Index Swap Rate [Member]
Derivative [Line Items]
Basis spread on variable rate		5.31%		5.31%
Derivative fixed interest rate		0.52%		0.52%
Variable interest rate		5.83%		5.83%

Segment Data	9 Months Ended
Segment Data	Sep. 30, 2023
Segment Data [Abstract]
Segment Data	Note 4 – Segment Data We conduct our business through two reportable segments: (i) health care distribution and (ii) technology and value-added services. These segments offer different products and services to the same customer base. Our global dental businesses serve office-based dental practitioners, dental laboratories, schools, government and other institutions. Our medical businesses serve physician offices, urgent care centers, ambulatory care sites, emergency medical technicians, dialysis centers, home health, federal and state governments and large enterprises, such as group practices and integrated delivery networks, among other providers across a wide range of specialties. Our dental and medical groups serve practitioners in 33 countries worldwide. The health care distribution reportable segment aggregates our global dental and medical operating segments. This segment distributes consumable products, dental specialty products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, personal protective equipment (“PPE”) and vitamins. Our global technology and value-added services reportable segment provides software, technology and other value- added services to health care practitioners. Our technology offerings include practice management software systems for dental and medical practitioners. Our value-added practice solutions include practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, practice technology, network and hardware services, as well as continuing education services for practitioners. The following tables present information about our reportable and operating segments: Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,882 $ 1,785 $ 5,737 $ 5,466 Medical 1,070 1,106 2,991 3,274 Total health care distribution 2,952 2,891 8,728 8,740 Technology and value-added services (2) 210 176 594 536 Total $ 3,162 $ 3,067 $ 9,322 $ 9,276 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Operating Income: Health care distribution $ 160 $ 179 $ 471 $ 579 Technology and value-added services 40 32 105 96 Total $ 200 $ 211 $ 576 $ 675

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Segment Data (Tables)	9 Months Ended
Segment Data (Tables)	Sep. 30, 2023
Segment Data [Abstract]
Business segment information	Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Net Sales: Health care distribution (1) Dental $ 1,882 $ 1,785 $ 5,737 $ 5,466 Medical 1,070 1,106 2,991 3,274 Total health care distribution 2,952 2,891 8,728 8,740 Technology and value-added services (2) 210 176 594 536 Total $ 3,162 $ 3,067 $ 9,322 $ 9,276 Consists of consumable products, small equipment, laboratory products, large equipment, equipment repair services, branded and generic pharmaceuticals, vaccines, surgical products, dental specialty products (including implant, orthodontic and endodontic products), diagnostic tests, infection-control products, PPE products and vitamins. (2) Consists of practice management software and other value-added products, which are distributed primarily to health care providers, practice consultancy, education, revenue cycle management and financial services on a non-recourse basis, e-services, continuing education services for practitioners, consulting and other services. Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Operating Income: Health care distribution $ 160 $ 179 $ 471 $ 579 Technology and value-added services 40 32 105 96 Total $ 200 $ 211 $ 576 $ 675

Net Sales from Contracts with Customers - Disaggregation of Revenue (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Disaggregation of Revenue [Abstract]
Net sales	$ 3,162	$ 3,067	$ 9,322	$ 9,276
North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,363	2,374	6,886	7,044
International [Member]
Disaggregation of Revenue [Abstract]
Net sales	799	693	2,436	2,232
Health Care Distribution [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,952	2,891	8,728	8,740
Health Care Distribution [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	2,178	2,219	6,367	6,575
Health Care Distribution [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	774	672	2,361	2,165
Health Care Distribution [Member] \| Dental [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,882	1,785	5,737	5,466
Health Care Distribution [Member] \| Dental [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,134	1,131	3,447	3,360
Health Care Distribution [Member] \| Dental [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	748	654	2,290	2,106
Health Care Distribution [Member] \| Medical [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,070	1,106	2,991	3,274
Health Care Distribution [Member] \| Medical [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	1,044	1,088	2,920	3,215
Health Care Distribution [Member] \| Medical [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	26	18	71	59
Technology and Value-Added Services [Member]
Disaggregation of Revenue [Abstract]
Net sales	210	176	594	536
Technology and Value-Added Services [Member] \| North America [Member]
Disaggregation of Revenue [Abstract]
Net sales	185	155	519	469
Technology and Value-Added Services [Member] \| International [Member]
Disaggregation of Revenue [Abstract]
Net sales	$ 25	$ 21	$ 75	$ 67

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 924
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 11.L)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479941/924-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-4

+ Details

Plan of Restructuring and Integration Costs	9 Months Ended
Plan of Restructuring and Integration Costs	Sep. 30, 2023
Plan of Restructuring and Integration Costs [Abstract]
Plan of Restructuring and Integration Costs	Note 10 – Plan of Restructuring On August 1, 2022, we committed to a restructuring plan focused on funding the priorities of the strategic plan and streamlining operations and other initiatives to increase efficiency. We revised our previous expectations of completion and now expect this initiative to extend through 2024. We are currently unable in good faith to make a determination of an estimate of the amount or range of amounts expected to be incurred in connection with these activities, both with respect to each major type of cost associated therewith and with respect to the total cost, or an estimate of the amount or range of amounts that will result in future cash expenditures. During the three months ended September 30, 2023 and September 24, 2022, we recorded restructuring costs of $ 11 million and $ 9 million, respectively. During the nine months ended September 30, 2023 and September 24, 2022, we recorded restructuring costs of $ 59 million and $ 9 million, respectively. The restructuring costs for these periods primarily related to severance and employee-related costs, accelerated amortization of right-of-use lease assets and fixed assets, and other lease exit costs. Included in restructuring costs for the nine months ended September 30, 2023 were immaterial amounts related to the disposal of an unprofitable U.S. business initiated during 2022 and completed during the first quarter of 2023. On August 26, 2022, we acquired Midway Dental Supply. In connection with this acquisition, during the three months ended September 24, 2022, we recorded integration costs of $ 1 million related to one-time employee and other costs, as well as restructuring charges of $ 2 million, which are included in the $ 9 million of restructuring charges discussed above. Restructuring and integration costs recorded for the three and nine months ended September 30, 2023 and September 24, 2022, consisted of the following: Three Months Ended September 30, 2023 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 3 - 1 4 Exit and other related costs 1 - - 1 Total restructuring and integration costs $ 10 $ - $ 1 $ 11 Three Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 2 - - 2 Exit and other related costs 1 - - 1 Integration employee-related and other costs - 1 - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ 10 Nine Months Ended September 30, 2023 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 36 $ - $ 4 $ 40 Accelerated depreciation and amortization 12 - 2 14 Exit and other related costs 3 - 1 4 Loss on disposal of a business 1 - - 1 Total restructuring and integration costs $ 52 $ - $ 7 $ 59 Nine Months Ended September 24, 2022 Health-Care Distribution Technology and Value-Added Services Restructuring Costs Integration Costs Restructuring Costs Total Severance and employee-related costs $ 6 $ - $ - $ 6 Accelerated depreciation and amortization 2 - - 2 Exit and other related costs 1 - - 1 Integration employee-related and other costs - 1 - 1 Total restructuring and integration costs $ 9 $ 1 $ - $ 10 The following table summarizes, by reportable segment, the activity related to the liabilities associated with our restructuring initiatives for the period ended September 30, 2023. The remaining accrued balance of restructuring costs as of September 30, 2023, which primarily relates to severance and employee-related costs, is included in accrued expenses: other within our condensed consolidated balance sheet. Liabilities related to exited leased facilities are recorded within our current and non-current operating lease liabilities within our condensed consolidated balance sheet. Technology and Health Care Value-Added Distribution Services Total Balance, December 31, 2022 $ 21 $ 3 $ 24 Restructuring and integration costs 52 7 59 Non-cash asset impairment and accelerated depreciation and amortization of right-of-use lease assets and other long-lived assets (12) (2) (14) Non-cash impairment on disposal of a business 1 - 1 Cash payments and other adjustments (37) (6) (43) Balance, September 30, 2023 $ 25 $ 2 $ 27

Business Acquisitions (Tables)	9 Months Ended
Business Acquisitions (Tables)	Sep. 30, 2023
S.I.N [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 326 Total consideration $ 326 Identifiable assets acquired and liabilities assumed: Current assets $ 75 Intangible assets 155 Other noncurrent assets 33 Current liabilities (33) Long-term debt (22) Deferred income taxes (55) Other noncurrent liabilities (27) Total identifiable net assets 126 Goodwill 200 Total net assets acquired $ 326
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Estimated Useful Lives (in years) Customer relationships and lists $ 78 10 Trademarks/ Tradenames 9 5 Non-compete agreements 1 5 Product development 38 7 Other 29 5 Total $ 155
Biotech Dental [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 216 Fair value of contributed equity share in a controlled subsidiary 25 Redeemable noncontrolling interests 182 Total consideration $ 423 Identifiable assets acquired and liabilities assumed: Current assets $ 80 Intangible assets 119 Other noncurrent assets 76 Current liabilities (51) Long-term debt (84) Deferred income taxes (38) Other noncurrent liabilities (22) Total identifiable net assets 80 Goodwill 343 Total net assets acquired $ 423
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Estimated Useful Lives (in years) Customer relationships and lists $ 60 10 Trademarks/ Tradenames 14 5 Non-compete agreements 1 5 Other 44 5 Total $ 119
Series Of Individually Immaterial Business Acquisitions [Member]
Business Acquisition [Line Items]
Summary of Estimated Fair Value of Consideration Paid and Net Assets Acquired	2023 Acquisition consideration: Cash $ 167 Deferred consideration 4 Estimated fair value of contingent consideration payable 6 Fair value of previously held equity method investment 29 Redeemable noncontrolling interests 77 Total consideration $ 283 Identifiable assets acquired and liabilities assumed: Current assets $ 32 Intangible assets 117 Other noncurrent assets 18 Current liabilities (23) Deferred income taxes (13) Long-term debt (8) Other noncurrent liabilities (10) Total identifiable net assets 113 Goodwill 170 Total net assets acquired $ 283
Summary of Identifiable Intangible Assets Acquired and Estimated Useful Lives	2023 Estimated Useful Lives (in years) Customer relationships and lists $ 76 2 - 12 Trademarks/ Tradenames 9 5 - 10 Non-compete agreements 2 5 Product development 7 7 Patents 1 10 Other 22 5 Total $ 117

Basis of Presentation (Policy)	9 Months Ended
Basis of Presentation (Policy)	Sep. 30, 2023
Basis of Presentation [Abstract]
Principles of Consolidation	Our condensed consolidated financial statements include the accounts of Henry Schein, Inc. and all of our controlled subsidiaries (“we”, “us” or “our”). All intercompany accounts and transactions are eliminated in consolidation. Investments in unconsolidated affiliates in which we have the ability to influence the operating or financial decisions are accounted for under the equity method. Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications, individually and in the aggregate, did not have a material impact on our condensed consolidated financial condition, results of operations or cash flows.
Use of Estimates	The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. The results of operations for the three and nine months ended September 30, 2023 are not necessarily indicative of the results to be expected for any other interim period or for the year ending December 30, 2023.
Consolidated Variable Interest Entity	We consolidate the results of operations and financial position of a trade accounts receivable securitization which we consider a Variable Interest Entity (“VIE”) because we are the primary beneficiary, and we have the power to direct activities that most significantly affect the economic performance and have the obligation to absorb the majority of the losses or benefits. For this VIE, the trade accounts receivable transferred to the VIE are pledged as collateral to the related debt. The creditors have recourse to us for losses on these trade accounts receivable. At September 30, 2023 and December 31, 2022, certain trade accounts receivable that can only be used to settle obligations of this VIE were $ 0 million and $ 327 million, respectively, and the liabilities of this VIE where the creditors have recourse to us were $ 0 million and $ 255 million, respectively.

Debt (Tables)	9 Months Ended
Debt (Tables)	Sep. 30, 2023
Debt [Abstract]
Schedule of Bank Credit Lines	September 30, December 31, 2023 2022 Revolving credit agreement $ - $ - Other short-term bank credit lines 12 103 Total $ 12 $ 103
Schedule of Long-Term Debt	September 30, December 31, 2023 2022 Private placement facilities $ 1,074 $ 699 U.S. trade accounts receivable securitization - 330 Term loan 745 - Various collateralized and uncollateralized loans payable with interest, in varying installments through 2023 at interest rates ranging from 0.00 % to 9.42 % at September 30, 2023 and ranging from 0.00 % to 3.50 % at December 31, 2022 58 7 Finance lease obligations 10 10 Total 1,887 1,046 Less current maturities (72) (6) Total long-term debt $ 1,815 $ 1,040
Schedule of Private Placement Facility Borrowings	Amount of Borrowing Borrowing Date of Borrowing Outstanding Rate Due Date January 20, 2012 $ 50 3.45 % January 20, 2024 December 24, 2012 50 3.00 December 24, 2024 June 16, 2017 100 3.42 June 16, 2027 September 15, 2017 100 3.52 September 15, 2029 January 2, 2018 100 3.32 January 2, 2028 September 2, 2020 100 2.35 September 2, 2030 June 2, 2021 100 2.48 June 2, 2031 June 2, 2021 100 2.58 June 2, 2033 May 4, 2023 75 4.79 May 4, 2028 May 4, 2023 75 4.84 May 4, 2030 May 4, 2023 75 4.96 May 4, 2033 May 4, 2023 150 4.94 May 4, 2033 Less: Deferred debt issuance costs (1) Total $ 1,074

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Accounts receivable, allowances for credit losses (in dollars)	$ 72	$ 65
Stockholders' equity:
Preferred stock, par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	1,000,000	1,000,000
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	480,000,000	480,000,000
Common stock, shares outstanding (in shares)	129,935,883	131,792,817

Related Party Transactions	9 Months Ended
Related Party Transactions	Sep. 30, 2023
Related Party Transactions [Abstract]
Related Party Transactions	Note 17 – Related Party Transactions In connection with the formation of Henry Schein One, LLC, our joint venture with Internet Brands, which was formed on July 1, 2018, we entered into a ten-year royalty agreement with Internet Brands whereby we will pay Internet Brands approximately $ 31 million annually for the use of their intellectual property. During the three and nine months ended September 30, 2023, we recorded $ 8 million and $ 23 million, respectively, in connection with costs related to this royalty agreement. During the three and nine months ended September 24, 2022, we recorded $ 8 million and $ 23 million, respectively, in connection with costs related to this royalty agreement. As of September 30, 2023 and December 31, 2022, Henry Schein One, LLC had a net payable balance due to Internet Brands of $ 10 million and $ 9 million, respectively, comprised of amounts related to results of operations and the royalty agreement. The components of this payable are recorded within accrued expenses: other, within our condensed consolidated balance sheets. During our normal course of business, we have interests in entities that we account for under the equity accounting method. During the three and nine months ended September 30, 2023, we recorded net sales of $ 10 million and $ 33 million, respectively, to such entities. During the three and nine months ended September 24, 2022, we recorded net sales of $ 13 million and $ 35 million, respectively, to such entities. During the three and nine months ended September 30, 2023, we purchased $ 1 million and $ 7 million, respectively, from such entities. During the three and nine months ended September 24, 2022, we purchased $ 1 million and $ 9 million, respectively, from such entities. At September 30, 2023 and December 31, 2022, we had an aggregate of $ 33 million and $ 36 million, respectively, due from our equity affiliates, and $ 5 million and $ 6 million, respectively, due to our equity affiliates. Certain of our facilities related to our acquisitions are leased from employees and minority shareholders. These leases are classified as operating leases and have a remaining lease term ranging from less than one year to 14 years. As of September 30, 2023, current and non-current liabilities associated with related party operating leases were $ 5 million and $ 24 million, respectively. Related party leases represented 6.9 % and 7.6 % of the total current and non-current operating lease liabilities.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

Stock-Based Compensation - Status of Unvested RSUs (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Time-Based Restricted Stock/Restricted Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	1,756,044
Granted (in shares) \| shares	417,873
Vested (in shares) \| shares	(429,425)
Forfeited (in shares) \| shares	(75,227)
Ending balance outstanding (in shares) \| shares	1,669,265
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 66.59
Granted (in dollars per share)	77.61
Vested (in dollars per share)	61.91
Forfeited (in dollars per share)	71.59
Ending balance outstanding (in dollars per share)	70.38
Aggregate intrinsic value	$ 74.25
Performance-Based Restricted Stock Units [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance outstanding (in shares) \| shares	520,916
Granted (in shares) \| shares	382,387
Vested (in shares) \| shares	(631,458)
Forfeited (in shares) \| shares	(55,510)
Ending balance outstanding (in shares) \| shares	216,335
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Beginning balance outstanding (in dollars per share)	$ 60.23
Granted (in dollars per share)	80.65
Vested (in dollars per share)	60.65
Forfeited (in dollars per share)	76.82
Ending balance outstanding (in dollars per share)	69.54
Aggregate intrinsic value	$ 74.25

Stock-Based Compensation (Tables)	9 Months Ended
Stock-Based Compensation (Tables)	Sep. 30, 2023
Stock-Based Compensation [Abstract]
Summary of Stock Option Activity Under the Plans	Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,117,574 $ 71.38 Exercised (21,204) 62.74 Forfeited (10,399) 78.32 Outstanding at end of period 1,085,971 $ 71.48 7.8 $ 8 Options exercisable at end of period 573,620 $ 68.39
Intrinsic Values	Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 508,728 $ 75.04 8.0 $ 3
Status of Unvested RSUs	Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 417,873 77.61 382,387 80.65 Vested (429,425) 61.91 (631,458) 60.65 Forfeited (75,227) 71.59 (55,510) 76.82 Outstanding at end of period 1,669,265 $ 70.38 $ 74.25 216,335 $ 69.54 $ 74.25

Redeemable Noncontrolling Interests	9 Months Ended
Redeemable Noncontrolling Interests	Sep. 30, 2023
Redeemable Noncontrolling Interests [Abstract]
Redeemable Noncontrolling Interests	Note 13 – Redeemable Noncontrolling Interests Some minority stockholders in certain of our subsidiaries have the right, at certain times, to require us to acquire their ownership interest in those entities at fair value. ASC 480-10 is applicable for noncontrolling interests where we are or may be required to purchase all or a portion of the outstanding interest in a consolidated subsidiary from the noncontrolling interest holder under the terms of a put option contained in contractual agreements. The components of the change in the redeemable noncontrolling interests for the nine months ended September 30, 2023 and the year ended December 31, 2022 are presented in the following table: September 30, December 31, 2023 2022 Balance, beginning of period $ 576 $ 613 Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interests in subsidiaries (19) (31) Increase in redeemable noncontrolling interests due to business acquisitions 281 4 Net income attributable to redeemable noncontrolling interests 11 21 Dividends declared (13) (21) Effect of foreign currency translation loss attributable to redeemable noncontrolling interests (1) (6) Change in fair value of redeemable securities (14) (4) Balance, end of period $ 821 $ 576

Segment Data (Details) $ in Millions	3 Months Ended		9 Months Ended
Segment Data (Details) $ in Millions	Sep. 30, 2023 USD ($) countries	Sep. 24, 2022 USD ($)	Sep. 30, 2023 USD ($) segments countries	Sep. 24, 2022 USD ($)
Segment Data [Abstract]
Number of reportable segments \| segments			2
Segment Reporting Information [Line Items]
Net sales	$ 3,162	$ 3,067	$ 9,322	$ 9,276
Operating income	200	211	576	675
Health Care Distribution [Member]
Segment Reporting Information [Line Items]
Net sales	2,952	2,891	8,728	8,740
Operating income	$ 160	179	$ 471	579
Number of countries served globally \| countries	33		33
Health Care Distribution [Member] \| Dental [Member]
Segment Reporting Information [Line Items]
Net sales	$ 1,882	1,785	$ 5,737	5,466
Health Care Distribution [Member] \| Medical [Member]
Segment Reporting Information [Line Items]
Net sales	1,070	1,106	2,991	3,274
Technology and Value-Added Services [Member]
Segment Reporting Information [Line Items]
Net sales	210	176	594	536
Operating income	$ 40	$ 32	$ 105	$ 96

Subsequent Event	9 Months Ended
Subsequent Event	Sep. 30, 2023
Subsequent Event [Abstract]
Subsequent Event	Note 18 – Subsequent Event On October 14, 2023, we became aware of a cybersecurity incident that primarily affected the operations of our North American and European dental and medical distribution businesses. Henry Schein One, our practice management software, revenue cycle management and patient relationship management solutions business was not affected, and our manufacturing businesses and our equipment sales and service operations were mostly unaffected. Once we became aware of the issue, we took steps to assess, contain and remediate this incident. Our distribution operations resumed and we reactivated our ecommerce platform. We also notified law enforcement and our customers and suppliers informing them of both the incident and management’s efforts to mitigate its impact on our daily operations. As previously disclosed, while our forensic investigation is still ongoing, we have determined that a data breach occurred. We are notifying potentially affected parties as appropriate. On November 22, 2023, we experienced a disruption to our ecommerce platform and related applications. The Company has restored its ecommerce platform and certain other applications in the United States, Canada and certain European countries. Our ecommerce platform in the remaining European countries and other applications are expected to follow shortly. We continue to review the impact of the incident on our business. As previously disclosed, we believe the incident will adversely impact our financial results for the fourth quarter and full year 2023. We maintain cyber insurance, subject to certain retentions and policy limitations. There can be no assurance that the insurance coverage we maintain is sufficient to cover costs and expenses related to this cybersecurity incident.

Comprehensive Income - Accumulated Other Comprehensive Income and Comprehensive Income Components (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022	Dec. 31, 2022
Attributable to Redeemable noncontrolling interests:
Foreign currency translation adjustment	$ (38)		$ (38)		$ (37)
Attributable to noncontrolling interests:
Foreign currency translation adjustment	(1)		(1)		(1)
Attributable to Henry Schein, Inc.:
Foreign currency translation adjustment	(252)		(252)		(236)
Unrealized gain from foreign currency hedging activities	7		7		5
Pension adjustment loss	(2)		(2)		(2)
Accumulated other comprehensive loss	(247)		(247)		(233)
Total Accumulated other comprehensive loss	(286)		(286)		$ (271)
Components of Comprehensive Income
Net Income (loss)	143	$ 162	419	$ 515
Foreign currency translation gain (loss)	(45)	(89)	(17)	(176)
Tax effect	0	0	0	0
Foreign currency translation gain (loss)	(45)	(89)	(17)	(176)
Unrealized gain (loss) from foreign currency hedging activities	9	15	3	27
Tax effect	(3)	(4)	(1)	(7)
Unrealized gain (loss) from foreign currency hedging activities	6	11	2	20
Pension adjustment gain	0	2	0	2
Tax effect	0	(1)	0	(1)
Pension adjustment gain	0	1	0	1
Comprehensive income	$ 104	$ 85	$ 404	$ 360

Derivatives and Hedging Activities	9 Months Ended
Derivatives and Hedging Activities	Sep. 30, 2023
Derivatives and Hedging Activities [Abstract]
Derivatives and Hedging Activities	Note 7 – Derivatives and Hedging Activities We are exposed to market risks as well as changes in foreign currency exchange rates as measured against the U.S. dollar and changes to the credit risk of the derivative counterparties. We attempt to minimize these risks by primarily using interest rate swaps, foreign currency forward contracts and by maintaining counter-party credit limits. These hedging activities provide only limited protection against interest rate, currency exchange and credit risks. Factors that could influence the effectiveness of our hedging programs include market interest rates, currency markets and availability of hedging instruments and liquidity of the credit markets. All interest rate swaps and foreign currency forward contracts that we enter into are components of hedging programs and are entered into for the sole purpose of hedging an existing or anticipated interest rate or currency exposure. We do not enter into such contracts for speculative purposes and we manage our credit risks by diversifying our counterparties, maintaining a strong balance sheet and having multiple sources of capital. During 2019 we entered into foreign currency forward contracts to hedge a portion of our euro-denominated foreign operations which are designated as net investment hedges. These net investment hedges offset the change in the U.S. dollar value of our investment in certain euro-functional currency subsidiaries due to fluctuating foreign exchange rates. Gains and losses related to these net investment hedges are recorded in accumulated other comprehensive loss within our condensed consolidated balance sheets. Amounts excluded from the assessment of hedge effectiveness are included in interest expense within our condensed consolidated statements of income. The aggregate notional value of this net investment hedge, which matured on November 16, 2023 , is approximately € 200 million. During the three months ended September 30, 2023 and September 24, 2022, we recorded an increase of $ 4 million and $ 15 million, respectively, within other comprehensive income related to these foreign currency forward contracts. During the nine months ended September 30, 2023 and September 24, 2022, we recorded an increase of $ 1 million and $ 26 million, respectively, within other comprehensive income related to these foreign currency forward contracts. On March 20, 2020 , we entered into a total return swap for the purpose of economically hedging our unfunded non- qualified SERP and our DCP. This swap will offset changes in our SERP and DCP liabilities. At the inception, the notional value of the investments in these plans was $ 43 million. At September 30, 2023, the notional value of the investments in these plans was $ 86 million. At September 30, 2023, the financing blended rate for this swap was based on the Secured Overnight Financing Rate (“SOFR”) of 5.31 % plus 0.52 %, for a combined rate of 5.83 %. For the three months ended September 30, 2023 and September 24, 2022, we have recorded a loss, within selling, general and administrative in our condensed consolidated statement of income, of approximately $ 7 million and $ 2 million, respectively, net of transaction costs, related to this undesignated swap. For the nine months ended September 30, 2023 and September 24, 2022, we have recorded a loss, within selling, general and administrative in our condensed consolidated statement of income, of approximately $ 1 million and $ 8 million, respectively, net of transaction costs, related to this undesignated swap. On July 11, 2023, we entered into interest rate swap agreements to hedge the cash flow of our variable rate $ 750 million floating debt term loan facility, with three years maturity, effectively changing the floating rate portion of our obligation to a fixed rate. Under the terms of the interest rate swap agreements, we receive variable interest payments based on the one-month Term SOFR rate and pay interest at a fixed rate. As of September 30, 2023, the notional value of the interest rate swap agreements was $ 745 million. For the three and nine months ended September 30, 2023, we recorded, within accumulated other comprehensive loss within our condensed consolidated balance sheets, a gain of $ 4 million related to the change in the fair value of these interest rate swap agreements, since we have designated these swaps agreements as cash flow hedges. Fluctuations in the value of certain foreign currencies as compared to the U.S. dollar may positively or negatively affect our revenues, gross margins, operating expenses and retained earnings, all of which are expressed in U.S. dollars. Where we deem it prudent, we engage in hedging programs using primarily foreign currency forward contracts aimed at limiting the impact of foreign currency exchange rate fluctuations on earnings. We purchase short-term (i.e., generally 18 months or less) foreign currency forward contracts to protect against currency exchange risks associated with intercompany loans due from our international subsidiaries and the payment of merchandise purchases to our foreign suppliers. We do not hedge the translation of foreign currency profits into U.S. dollars, as we regard this as an accounting exposure, not an economic exposure. Amounts related to our hedging activities are recorded in prepaid expenses and other and/or accrued expenses: other within our condensed consolidated balance sheets. Our hedging activities have historically not had a material impact on our condensed consolidated financial statements. Accordingly, additional disclosures related to derivatives and hedging activities required by ASC 815 have been omitted.

Stock-Based Compensation	9 Months Ended
Stock-Based Compensation	Sep. 30, 2023
Stock-Based Compensation [Abstract]
Stock-Based Compensation	Note 12 – Stock-Based Compensation Stock-based awards are provided to certain employees under the terms of our 2020 Stock Incentive Plan and to non-employee directors under the terms of our 2023 Non-Employee Director Stock Incentive Plan (formerly known as the 2015 Non-Employee Director Stock Incentive Plan) (together, the “Plans”). The Plans are administered by the Compensation Committee of the Board of Directors (the “Compensation Committee”). Historically, equity- based awards to our employees have been granted solely in the form of time-based and performance-based restricted stock units (“RSUs”) with the exception of our 2021 plan year in which non-qualified stock options were issued in place of performance-based RSUs. In 2022, we granted time-based and performance-based RSUs, as well as non-qualified stock options. For our 2023 plan year, we returned to granting our employees equity-based awards solely in the form of time-based and performance-based RSUs. Our non-employee directors receive equity-based awards solely in the form of time-based RSUs. RSUs are stock-based awards granted to recipients with specified vesting provisions. In the case of RSUs, common stock is delivered on or following satisfaction of vesting conditions. We issue RSUs to employees that primarily vest (i) solely based on the recipient’s continued service over time, primarily with four -year cliff vesting and/or (ii) based on achieving specified performance measurements and the recipient’s continued service over time, primarily with three -year cliff vesting. RSUs granted to our non-employee directors primarily are granted with 12 -month cliff vesting. For these RSUs, we recognize the cost as compensation expense on a straight-line basis. With respect to time-based RSUs, we estimate the fair value based on our closing stock price on the date of grant. With respect to performance-based RSUs, the number of shares that ultimately vest and are received by the recipient is based upon our performance as measured against specified targets over a specified period, as determined by the Compensation Committee. Although there is no guarantee that performance targets will be achieved, we estimate the fair value of performance-based RSUs based on our closing stock price at time of grant. Each of the Plans provide for certain adjustments to the performance measurement in connection with awards under the Plans. With respect to the performance-based RSUs granted under our 2020 Stock Incentive Plan, such performance measurement adjustments relate to significant events, including, without limitation, acquisitions, divestitures, new business ventures, certain capital transactions (including share repurchases), differences in budgeted average outstanding shares (other than those resulting from capital transactions referred to above), restructuring costs, if any, certain litigation settlements or payments, if any, changes in accounting principles or in applicable laws or regulations, changes in income tax rates in certain markets, foreign exchange fluctuations, the financial impact either positive or negative, of the difference in projected earnings generated by COVID-19 test kits (solely with respect to performance-based RSUs granted in the 2022 and 2023 plan years) and impairment charges (solely with respect to performance-based RSUs granted in the 2023 plan year), and unforeseen events or circumstances affecting us. Over the performance period, the number of shares of common stock that will ultimately vest and be issued and the related compensation expense is adjusted upward or downward based upon our estimation of achieving such performance targets. The ultimate number of shares delivered to recipients and the related compensation cost recognized as an expense will be based on our actual performance metrics as defined under the Plans. Stock options are awards that allow the recipient to purchase shares of our common stock at a fixed price following vesting of the stock options. Stock options were granted at an exercise price equal to our closing stock price on the date of grant. Stock options issued in 2021 and 2022 vest one-third per year based on the recipient’s continued service, subject to the terms and conditions of the 2020 Stock Incentive Plan, are fully vested three years from the grant date and have a contractual term of ten years from the grant date, subject to earlier termination of the term upon certain events. Compensation expense for these stock options is recognized using a graded vesting method. We estimated the fair value of stock options using the Black-Scholes valuation model. During the nine months ended September 30, 2023 we did no t grant any stock options. Our accompanying condensed consolidated statements of income reflect pre-tax share-based compensation expense of $ 14 million ($ 11 million after-tax) and $ 38 million ($ 30 million after-tax) for the three and nine months ended September 30, 2023, respectively. For the three and nine months ended September 24, 2022, we recorded pre-tax share-based compensation expense of $ 17 million ($ 13 million after-tax) and $ 44 million ($ 34 million after-tax), respectively. Total unrecognized compensation cost related to unvested awards as of September 30, 2023 was $ 83 million, which is expected to be recognized over a weighted-average period of approximately 2.5 years. Our accompanying condensed consolidated statements of cash flows present our stock-based compensation expense as an adjustment to reconcile net income to net cash provided by operating activities for all periods presented. In the accompanying condensed consolidated statements of cash flows, there were no benefits associated with tax deductions in excess of recognized compensation as a cash inflow from financing activities for the nine months ended September 30, 2023 and September 24, 2022, respectively. We have not declared cash dividends on our stock in the past and we do not anticipate declaring cash dividends in the foreseeable future. The expected stock price volatility is based on implied volatilities from traded options on our stock, historical volatility of our stock, and other factors. The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant in conjunction with considering the expected life of options. The six -year expected life of the options was determined using the simplified method for estimating the expected term as permitted under SAB Topic 14. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by recipients of stock options, and subsequent events are not indicative of the reasonableness of the original estimates of fair value made by us. The following table summarizes the stock option activity during the nine months ended September 30, 2023: Stock Options Weighted Average Weighted Average Aggregate Exercise Remaining Contractual Intrinsic Shares Price Life (in years) Value Outstanding at beginning of period 1,117,574 $ 71.38 Exercised (21,204) 62.74 Forfeited (10,399) 78.32 Outstanding at end of period 1,085,971 $ 71.48 7.8 $ 8 Options exercisable at end of period 573,620 $ 68.39 Weighted Average Weighted Average Aggregate Number of Exercise Remaining Contractual Intrinsic Options Price Life (in years) Value Vested or expected to vest 508,728 $ 75.04 8.0 $ 3 The following tables summarize the activity of our unvested RSUs for the nine months ended September 30, 2023: Time-Based Restricted Stock Units Performance-Based Restricted Stock Units Weighted Average Weighted Average Grant Date Fair Intrinsic Value Grant Date Fair Intrinsic Value Shares/Units Value Per Share Per Share Shares/Units Value Per Share Per Share Outstanding at beginning of period 1,756,044 $ 66.59 520,916 $ 60.23 Granted 417,873 77.61 382,387 80.65 Vested (429,425) 61.91 (631,458) 60.65 Forfeited (75,227) 71.59 (55,510) 76.82 Outstanding at end of period 1,669,265 $ 70.38 $ 74.25 216,335 $ 69.54 $ 74.25

Plan of Restructuring and Integration Costs - Schedule of Restructuring Costs and Integration Costs (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 11,000,000	$ 9,000,000	$ 59,000,000	$ 9,000,000
Restructuring and integration related costs	11,000,000	10,000,000	59,000,000	10,000,000
Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and integration related costs	6,000,000	6,000,000	40,000,000	6,000,000
Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and integration related costs	4,000,000	2,000,000	14,000,000	2,000,000
Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and integration related costs	1,000,000	1,000,000	4,000,000	1,000,000
Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and integration related costs			1,000,000
Integration Employee-Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and integration related costs		1,000,000		1,000,000
Health Care Distribution [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	10,000,000	9,000,000	52,000,000	9,000,000
Integration Costs		1,000,000		1,000,000
Restructuring and integration related costs			52,000,000
Health Care Distribution [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	6,000,000	6,000,000	36,000,000	6,000,000
Health Care Distribution [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	3,000,000	2,000,000	12,000,000	2,000,000
Health Care Distribution [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000	1,000,000	3,000,000	1,000,000
Health Care Distribution [Member] \| Disposal of Business [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs			1,000,000
Health Care Distribution [Member] \| Integration Employee-Related and Other Costs [Member]
Restructuring Cost and Reserve [Line Items]
Integration Costs		$ 1,000,000		$ 1,000,000
Technology and Value-Added Services [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		7,000,000
Restructuring and integration related costs			7,000,000
Technology and Value-Added Services [Member] \| Severance and Employee-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	0		4,000,000
Technology and Value-Added Services [Member] \| Accelerated Depreciation and Amortization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	1,000,000		2,000,000
Technology and Value-Added Services [Member] \| Exit and Other Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Costs	$ 0		$ 1,000,000

Business Acquisitions - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Jul. 05, 2023	Apr. 05, 2023	Sep. 24, 2022
Business Acquisition [Line Items]
Recognized gain related to remeasurement to fair value of previously held equity investment	$ 18
Acquisition costs	$ 18			$ 6
S.I.N [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired		100.00%
Biotech Dental [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired			57.00%
Series Of Individually Immaterial Business Acquisitions [Member] \| Minimum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired	51.00%
Series Of Individually Immaterial Business Acquisitions [Member] \| Maximum [Member]
Business Acquisition [Line Items]
Percentage of voting interest acquired	100.00%

Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2023
Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards [Abstract]
Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards	Note 2 – Critical Accounting Policies, Accounting Standard Adopted, and Recently Issued Accounting Standards Critical Accounting Policies There have been no material changes in our critical accounting policies during the nine months ended September 30, 2023, as compared to the critical accounting policies described in Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022. Accounting Standard Adopted During the quarter ended September 30, 2023, we adopted Accounting Standards Codification (“ASC”) Topic 848, Reference Rate Reform (Topic 848). The adoption of Topic 848 did not have a material impact on our condensed consolidated financial statements. Recently Issued Accounting Standards In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, “Liabilities – Supplier Finance Programs (Subtopic 405-50): Disclosure of Supplier Finance Program Obligations,” which will increase transparency of supplier finance programs by requiring entities that use such programs in connection with the purchase of goods and services to disclose certain qualitative and quantitative information about such programs. ASU 2022-04 is effective for fiscal years beginning after December 15, 2022, including interim periods within those fiscal years, except for amended roll forward information, which is effective for fiscal years beginning after December 15, 2023. We do not expect that the requirements of this guidance will have a material impact on our condensed consolidated financial statements.

- Definition

The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 5
-Subparagraph (SAB Topic 11.M.Q2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 926
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483194/926-20-65-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480530/250-10-S99-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 250
-Publisher FASB
-URI https://asc.fasb.org//250/tableOfContent

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(1)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (d)(2)
-SubTopic 20
-Topic 310
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

+ Details

Earnings Per Share (Tables)	9 Months Ended
Earnings Per Share (Tables)	Sep. 30, 2023
Earnings Per Share [Abstract]
Reconciliation of Shares used in Calculating Earnings per Share Basic and Diluted	Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Basic 130,388,353 135,608,678 130,888,717 136,731,413 Effect of dilutive securities: Stock options and restricted stock units 1,053,782 1,475,371 1,260,455 1,756,841 Diluted 131,442,135 137,084,049 132,149,172 138,488,254
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Stock options 424,005 482,497 426,237 310,565 Restricted stock units 7,362 445,994 15,072 261,718 Total anti-dilutive securities excluded from earnings per share computation 431,367 928,491 441,309 572,283

Debt - Schedule of Bank Credit Lines (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Line of Credit Facility [Line Items]
Bank Credit lines	$ 12	$ 103
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	0	0
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Bank Credit lines	$ 12	$ 103

Cover Page - shares	9 Months Ended
Cover Page - shares	Sep. 30, 2023	Nov. 13, 2023
Cover [Abstract]
Entity Central Index Key	0001000228
Amendment Flag	false
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-30
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity Registrant Name	HENRY SCHEIN, INC.
Entity File Number	0-27078
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-3136595
Entity Address, Address Line One	135 Duryea Road
Entity Address, City or Town	Melville
Entity Address, State or Province	NY
Entity Address, Postal Zip Code	11747
City Area Code	631
Local Phone Number	843-5500
Title of 12(b) Security	Common Stock, par value $.01 per share
Trading Symbol	HSIC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		129,938,341

Redeemable Noncontrolling Interests - Components of the Change in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022	Dec. 31, 2022
Components of the change in the redeemable noncontrolling interests [Abstract]
Balance, beginning of period			$ 576	$ 613	$ 613
Decrease in redeemable noncontrolling interests due to acquisitions of noncontrolling interest in subsidiaries			(19)		(31)
Increase in redeemable noncontrolling interests due to business acquisitions			281		4
Net income attributable to redeemable noncontrolling interests	$ 2	$ 10	11	19	21
Dividends declared			(13)		(21)
Effect of foreign currency translation loss attributable to redeemable noncontrolling interests	(2)	$ (6)	(1)	$ (13)	(6)
Change in fair value of redeemable securities			(14)		(4)
Balance, end of period	$ 821		$ 821		$ 576

- Definition

Carrying amount, attributable to parent and noncontrolling interests, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.

+ References + Details

Net Sales from Contracts with Customers (Tables)	9 Months Ended
Net Sales from Contracts with Customers (Tables)	Sep. 30, 2023
Net Sales from Contracts with Customers [Abstract]
Disaggregation of Revenue	Three Months Ended Nine Months Ended September 30, 2023 September 30, 2023 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,134 $ 748 $ 1,882 $ 3,447 $ 2,290 $ 5,737 Medical 1,044 26 1,070 2,920 71 2,991 Total health care distribution 2,178 774 2,952 6,367 2,361 8,728 Technology and value-added services 185 25 210 519 75 594 Total net sales $ 2,363 $ 799 $ 3,162 $ 6,886 $ 2,436 $ 9,322 Three Months Ended Nine Months Ended September 24, 2022 September 24, 2022 North America International Global North America International Global Net sales: Health care distribution Dental $ 1,131 $ 654 $ 1,785 $ 3,360 $ 2,106 $ 5,466 Medical 1,088 18 1,106 3,215 59 3,274 Total health care distribution 2,219 672 2,891 6,575 2,165 8,740 Technology and value-added services 155 21 176 469 67 536 Total net sales $ 2,374 $ 693 $ 3,067 $ 7,044 $ 2,232 $ 9,276

Supplemental Cash Flow Information (Tables)	9 Months Ended
Supplemental Cash Flow Information (Tables)	Sep. 30, 2023
Supplemental Cash Flow information [Abstract]
Cash paid for interest and income taxes	Nine Months Ended September 30, September 24, 2023 2022 Interest $ 52 $ 29 Income taxes 178 235

Legal Proceedings	9 Months Ended
Legal Proceedings	Sep. 30, 2023
Legal Proceedings [Abstract]
Legal Proceedings	Note 11 – Legal Proceedings Henry Schein, Inc. has been named as a defendant in multiple opioid related lawsuits (currently less than one- hundred and seventy-five ( 175 ); one or more of Henry Schein, Inc.’s subsidiaries is also named as a defendant in a number of those cases). Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false advertising campaign to expand the market for such drugs and their own market share and that the entities in the supply chain (including Henry Schein, Inc. and its subsidiaries) reaped financial rewards by refusing or otherwise failing to monitor appropriately and restrict the improper distribution of those drugs. These actions consist of some that have been consolidated within the MultiDistrict Litigation (“MDL”) proceeding In Re National Prescription Opiate Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently stayed, and others which remain pending in state courts and are proceeding independently and outside of the MDL. At this time, the following cases are set for trial: the action filed by Mobile County Board of Health, et al. in Alabama state court, which has been set for a jury trial on August 12, 2024; and the action filed by Florida Health Sciences Center, Inc. (and 26 other hospitals located throughout the State of Florida) in Florida state court, which is currently scheduled for a jury trial in September 2025. Of Henry Schein’s 2022 net sales of approximately $ 12.6 billion from continuing operations, sales of opioids represented less than two-tenths of 1 percent. Opioids represent a negligible part of our business. We intend to defend ourselves vigorously against these actions. In August 2022, Henry Schein received a Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia, seeking documents in connection with an investigation of possible violations of the Federal Food, Drug & Cosmetic Act by Butler Animal Health Supply, LLC (“Butler”), a former subsidiary of Henry Schein. The investigation relates to the sale of veterinary prescription drugs to certain customers. In October 2022, Henry Schein received a second Grand Jury Subpoena from the United States Attorney’s Office for the Western District of Virginia. The October Subpoena seeks documents relating to payments Henry Schein received from Butler or Covetrus, Inc. (“Covetrus”). Butler was spun off into a separate company and became a subsidiary of Covetrus in 2019 and is no longer owned by Henry Schein. We are cooperating with the investigation. From time to time, we may become a party to other legal proceedings, including, without limitation, product liability claims, employment matters, commercial disputes, governmental inquiries and investigations (which may in some cases involve our entering into settlement arrangements or consent decrees), and other matters arising out of the ordinary course of our business. While the results of any legal proceeding cannot be predicted with certainty, in our opinion none of these other pending matters are currently anticipated to have a material adverse effect on our consolidated financial position, liquidity or results of operations. As of September 30, 2023, we had accrued our best estimate of potential losses relating to claims that were probable to result in liability and for which we were able to reasonably estimate a loss. This accrued amount, as well as related expenses, was not material to our financial position, results of operations or cash flows. Our method for determining estimated losses considers currently available facts, presently enacted laws and regulations and other factors, including probable recoveries from third parties.

Earnings Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	431,367	928,491	441,309	572,283
Stock Options [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	424,005	482,497	426,237	310,565
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from EPS computation	7,362	445,994	15,072	261,718

Comprehensive Income - Total Comprehensive Income, Net of Applicable Taxes (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
Comprehensive Income Net Of Applicable Taxes [Abstract]
Comprehensive income attributable to Henry Schein, Inc.	$ 100	$ 79	$ 384	$ 350
Comprehensive income attributable to noncontrolling interests	4	2	10	4
Comprehensive income attributable to Redeemable noncontrolling interests	0	4	10	6
Comprehensive income	$ 104	$ 85	$ 404	$ 360

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

Earnings Per Share	9 Months Ended
Earnings Per Share	Sep. 30, 2023
Earnings Per Share [Abstract]
Earnings Per Share	Note 15 – Earnings Per Share Basic earnings per share is computed by dividing net income attributable to Henry Schein, Inc. by the weighted- average number of common shares outstanding for the period. Our diluted earnings per share is computed similarly to basic earnings per share, except that it reflects the effect of common shares issuable for presently unvested RSUs and upon exercise of stock options using the treasury stock method in periods in which they have a dilutive effect. A reconciliation of shares used in calculating earnings per basic and diluted share follows: Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Basic 130,388,353 135,608,678 130,888,717 136,731,413 Effect of dilutive securities: Stock options and restricted stock units 1,053,782 1,475,371 1,260,455 1,756,841 Diluted 131,442,135 137,084,049 132,149,172 138,488,254 The number of antidilutive securities that were excluded from the calculation of diluted weighted average common shares outstanding are as follows: Three Months Ended Nine Months Ended September 30, September 24, September 30, September 24, 2023 2022 2023 2022 Stock options 424,005 482,497 426,237 310,565 Restricted stock units 7,362 445,994 15,072 261,718 Total anti-dilutive securities excluded from earnings per share computation 431,367 928,491 441,309 572,283

Net Sales from Contracts with Customers - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Net Sales from Contracts with Customers [Abstract]
Contract with Customer, Liability, Current	$ 86	$ 86
Contract with Customer, Liability, Noncurrent	9	$ 8
Contract with Customer, Liability, Revenue Recognized	$ 70

Debt - Revolving Credit Agreement Narrative (Details) - USD ($)	3 Months Ended	6 Months Ended
	Sep. 30, 2023	Jul. 01, 2023	Dec. 31, 2022
Revolving Credit Agreement [Member]
Line of Credit Facility [Line Items]
Line of credit initiation date	Jul. 11, 2023	Aug. 20, 2021
Credit facility borrowing capacity		$ 1,000,000,000.0
Credit facility expiration date	Jul. 11, 2028	Aug. 20, 2026
Borrowings	$ 0		$ 0
Outstanding letters of credit provided to third parties	9,000,000		9,000,000
Other Short-Term Credit Lines [Member]
Line of Credit Facility [Line Items]
Credit facility borrowing capacity	$ 366,000,000		$ 402,000,000

- Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References + Details

Legal Proceedings - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
Legal Proceedings - Narrative (Details) $ in Millions	Sep. 30, 2023 USD ($) claims	Sep. 24, 2022 USD ($)	Sep. 30, 2023 USD ($) claims	Sep. 24, 2022 USD ($)
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues	$ 3,162	$ 3,067	$ 9,322	$ 9,276
Maximum [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Loss Contingency, Pending Claims, Number \| claims	175		175
Actions Consolidated in the MultiDistrict Litigation [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Maximum sales of opioids in North America during the year, percentage			0.20%
Actions Consolidated in the MultiDistrict Litigation [Member] \| Continuing Operations [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Revenues			$ 12,600
Other Hospitals Located throughout Florida [Member]
Loss Contingency, Information about Litigation Matters [Abstract]
Number of plaintiffs			26

- Definition

+ References

+ Details

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 24, 2022	Sep. 30, 2023	Sep. 24, 2022
CONDENSED CONSOLIDATED STATEMENTS OF INCOME [Abstract]
Net sales	$ 3,162	$ 3,067	$ 9,322	$ 9,276
Cost of sales	2,167	2,153	6,386	6,444
Gross profit	995	914	2,936	2,832
Operating expenses:
Selling, general and administrative	725	648	2,149	2,010
Depreciation and amortization	59	45	152	137
Restructuring and integration costs	11	10	59	10
Operating income	200	211	576	675
Other income (expense):
Interest income	6	1	12	5
Interest expense	(25)	(8)	(58)	(23)
Other, net	(2)	1	(2)	1
Income before taxes, equity in earnings of affiliates and noncontrolling interests	179	205	528	658
Income taxes	(39)	(46)	(119)	(155)
Equity in earnings of affiliates	3	3	10	12
Net income	143	162	419	515
Less: Net income attributable to noncontrolling interests	(6)	(12)	(21)	(24)
Net income attributable to Henry Schein, Inc.	$ 137	$ 150	$ 398	$ 491
Earnings per share attributable to Henry Schein, Inc.:
Basic (in dollars per share)	$ 1.06	$ 1.10	$ 3.04	$ 3.59
Diluted (in dollars per share)	$ 1.05	$ 1.09	$ 3.02	$ 3.55
Weighted-average common shares outstanding:
Basic (in shares)	130,388,353	135,608,678	130,888,717	136,731,413
Diluted (in shares)	131,442,135	137,084,049	132,149,172	138,488,254

Stock-Based Compensation - Intrinsic Values (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options \| shares	508,728
Weighted Average Exercise Price \| $ / shares	$ 75.04
Weighted Average Remaining Contractual Life (in years)	8 years
Intrinsic Value Per Share \| $	$ 3

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details